Document:

EX-10.18

 Exhibit 10.18 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 EXCLUSIVE
LICENSE AGREEMENT 
 BAYLOR COLLEGE OF MEDICINE 

BELLICUM PHARMACEUTICALS, INC. 
  

	RE:	BLG 06-028, “Inducible Toll-like Receptors and Composite Costimulatory Receptors for Unified, Broadly Applicable Immunotherapy”, developed by David M. Spencer, Kevin M. Slawin, Natalia Lapteva, and
Priyadharshini Narayanan. Disclosed to BCM on [...***...]. 

 This Exclusive License Agreement (hereinafter called
“Agreement”), to be effective as of the 27th day of June, 2010 (hereinafter called “Agreement Date”), is by and between Baylor College of Medicine (hereinafter called
“BAYLOR”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and Bellicum Pharmaceuticals, Inc., a corporation organized under the laws of Delaware and having a principal place
of business at 6400 Fannin Street, Suite 2300 Houston, TX 77030, and its Affiliates (hereinafter, collectively referred to as “BELLICUM”). 

WITNESSETH: 
 WHEREAS, BAYLOR, by
virtue of its relationship with its faculty, staff and students and conveyances with the Developers (as defined below) and under and pursuant to the terms and provisions of its Policy on Inventions and Patents, is the owner of certain right, title
and interest in and to the Subject Technology and Patent Rights (as defined below); and 
 WHEREAS, BAYLOR granted certain rights in the
Subject Technology and Patent Rights to [...***...] under the terms of the Material Transfer Agreement between Baylor College of Medicine and [...***...], dated [...***...]; and 

WHEREAS, BAYLOR is willing to grant a worldwide, exclusive license to all of the right, title and interest owned by BAYLOR as of the Agreement
Date in the Subject Technology and Patent Rights to BELLICUM on the terms set forth herein; and 
 WHEREAS, BELLICUM desires to obtain said
exclusive license under the Subject Technology and Patent Rights; and 
 NOW, THEREFORE, for and in consideration of the foregoing and
rights and obligations hereafter, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto expressly agree as follows: 

  
 ***Confidential
Treatment Requested 

  
 -1- 

 1. DEFINITIONS AS USED HEREIN 

1.1 “Affiliates” shall mean any corporation, partnership, joint venture or other entity of which the common stock or other
equity ownership thereof is 50% or more owned by BELLICUM. 
 1.2 “Confidential Information” shall mean any
proprietary and secret ideas, proprietary technical information, know-how and proprietary commercial information or other similar proprietary information. 

1.3 “Developers” shall mean David M. Spencer, Kevin M. Slawin, Natalia Lapteva, and Priyadharshini
Narayanan, employees of BAYLOR at the time the invention was disclosed. 
 1.4 “Field” shall mean all fields of use.

 1.5 “Legal Costs” shall mean all legal fees and expenses, filing or maintenance fees, assessments and all other costs and
expenses related to prosecuting, obtaining and maintaining patent protection on the Patent Rights in the United States and foreign countries. 

1.6 “Licensed Product(s)” will mean (i) any product that the manufacture, use or sale of which would constitute, but for
the license granted to BELLICUM, or sublicense granted to a sublicensee, under this Agreement, an infringement of any Valid Claim of the Patent Rights; and/or (ii) any method the practice of which would constitute, but for the license granted
to BELLICUM, or sublicense granted to a sublicensee, under this Agreement, an infringement of any Valid Claim of the Patent Rights. 

1.7 “Net Sales” shall mean the gross sales price invoiced to or received (whichever occurs first) from customers, who are not
Affiliates, of Licensed Product by BELLICUM or sublicensees, less: 
  

	 	(i)	[...***...]; 

  

	 	(ii)	[...***...]; 

  

	 	(iii)	[...***...]; 

  

	 	(iv)	[...***...]; and 

  

	 	(v)	[...***...]; 

  
 ***Confidential
Treatment Requested 

  
 -2- 

 The term “Net Sales” in the case of non-cash sales, shall mean the fair market value of all equivalent
or other consideration received by BELLICUM or sublicensees for the sale, lease or transfer of Licensed Product. 
 1.8
“Party” shall mean either BELLICUM or BAYLOR, and the “Parties” shall mean BELLICUM and BAYLOR. 
 1.9
“Patent Rights” shall mean all right, title and interest owned by BAYLOR as of the Agreement Date in patent applications filed before, on or after the Agreement Date, that pertain to the Subject Technology, including: 

(a) PCT Patent Application No. PCT/US2007/081963, “Methods and Compositions for Generating an Immune Response by Inducing CD40 and Pattern Recognition
Receptors and Adaptors Thereof”,” naming David M. Spencer and Natalia Lapteva as inventors, and filed 10/19/2007, which claims priority to U.S. Provisional Patent Application No. 60/862,211, filed 10/19/2006; U.S. Provisional Patent
Application No. 60/895,088, filed 03/15/2007; United States Patent Application No. 12/445,939, International filing date 10/19/2007; Australian Patent Application No. 2007310946, International filing date 10/19/2007; Canadian Patent
Application No. 2,666,667, International filing date 10/19/2007; European Patent Convention Application No. 07844466.8, International filing date 10/19/2007; and Hong Kong Patent Application No. 10100140.7, International filing date
10/19/2008; 
 (b) United States Patent Application No. 12/563,991, “Methods and Compositions for Generating an Immune Response by Inducing CD40
and Pattern Recognition Receptor Adapters,” naming David Spencer and Priyadharshini Narayanan as inventors, and filed 9/21/09. Claims priority to U.S. Provisional Patent Application No. 61/099,163, filed 9/22/08, U.S. Provisional Patent
Application No. 61/153,562, filed 2/18/09, and U.S. Provisional Patent Application No. 61/181,572, filed 5/27/09; 
 (c) PCT Patent Application No.
PCT/US2009/057738, “Methods and Compositions for Generating an Immune Response by Inducing CD40 and Pattern Recognition Receptor Adapters,” naming David Spencer and Priyadharshini Narayan as inventors, and filed 9/21/09, which claims
priority to U.S. Provisional Patent Application No. 61/099,163, filed 9/22/08, U.S. Provisional Patent Application No. 61/153,562, filed 2/18/09, and U.S. Provisional Patent Application No. 61/181,572, filed 5/27/09; 

(d) United States Provisional Application No. 61/325,127, entitled “Method for Treating Solid Tumors,” naming Kevin Slawin, David Spencer and
Natalia Lapteva as inventors, and filed April 16, 2010, subject to limitations described in Section 1.9(f); and 
 (e) (i) all United States
counterparts and foreign counterparts of patent applications listed in the foregoing clauses (a) to (d); (ii) all other patents and patent applications in any country that claim, cover or describe the Subject Technology and/or subject
matter disclosed in patent applications of (a) to (d) and (e)(i) and are owned or controlled by BAYLOR; (iii) all pending patent applications anywhere in the world that claim common priority with any patent or patent application of
the foregoing clauses (a) to (d), (e)(i) and 

  
 -3- 

 (e) (ii); (iv) all patents that have issued or in the future issue from any of the patent applications
described in the foregoing clauses (a) to (d) and (e)(i)-(iii), including without limitation, utility models, design patents and certificates of invention; and (v) all divisionals, continuations, continuations-in-part, reissues,
reexaminations, renewals, extensions or additions to the patents and patent application listed and described in the foregoing clauses (a) to (d) and (e)(i)-(iv). As used herein, the phrase “pending patent applications” shall be
construed to include provisional applications. 
 (f) Patent Rights provided in Section 1.9(d), and Sections 1.9(e)(i)-(v) as they pertain to Section 1.9(d),
extend only to products containing a MyD88 nucleotide sequence or MyD88 amino acid sequence, compositions that include such products, and methods for making and using such compositions and products. 

1.10 “Subject Technology” shall mean and include all right, title and interest owned by BAYLOR as of the Agreement Date in any
technology, biological materials, methods, documents, materials, tests, know-how and all confidential information existing as of the Agreement Date pertaining to the following technology disclosures: 

BLG 06-028, “Inducible Toll-like Receptors and Composite Costimulatory Receptors for Unified, Broadly Applicable Immunotherapy”,
developed by David M. Spencer, Kevin M. Slawin, Natalia Lapteva, and Priyadharshini Narayanan. Disclosed to BCM on [...***...]. 
 1.11
“Sublicensing Revenue” shall mean all cash and non-cash items not earmarked for a specific purpose, paid to BELLICUM which constitute advance considerations for sublicensing rights to Licensed Product(s) granted by BELLICUM, but
exclude any amounts (i) [...***...], or (ii) [...***...], (iii) [...***...], (iv) [...***...], and (v) [...***...]. 

1.12 “Valid Claim” means a claim of an issued and unexpired patent within the Patent Rights that has not been held revoked,
unenforceable, unpatentable or invalid by a final decision of a court of competent jurisdiction or by a final decision of a patent office and that has not been admitted to be invalid or unenforceable through reissue, reexamination, disclaimer or
otherwise. 
 2. GRANT OF LICENSE 

2.1 Grant. Subject to the reservations of rights set forth in Paragraph 2.2, BAYLOR hereby grants to BELLICUM, and BELLICUM
hereby accepts, an exclusive, worldwide, sublicensable, fee-bearing and royalty-bearing license under the Patent Rights and Subject Technology, to make, have made, use, import, export, distribute, research, develop, obtain regulatory approval,
manufacture, have manufactured, offer for sale and sell Licensed Products. 

  
 ***Confidential
Treatment Requested 

  
 -4- 

 2.2 Restrictions. The grant in Paragraph 2.1 shall be further subject to,
restricted by and non-exclusive with respect to; 
 (i) the making or use of the Subject Technology and Patent Rights by BAYLOR for
non-commercial research, patient care, teaching and other educationally related purposes; 
 (ii) any non-exclusive license of the Subject
Technology and/or Patent Rights that BAYLOR grants to other academic or research institutions for non-commercial research purposes; and 

(iii) any non-exclusive license of the Subject Technology and/or Patent Rights that BAYLOR is required by law or regulation to grant to the
United States of America or to a foreign state pursuant to an existing or future treaty with the United States of America; and 
 (iv) the
non-exclusive, worldwide, paid-up license granted to [...***...] under the terms of the Material Transfer Agreement between Baylor College of Medicine and [...***...], dated [...***...]. 

2.3 Government Reservation. Rights under this Agreement are subject to rights required to be granted to the Government of the
United States of America pursuant to 35 USC Section 200-212, including a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the subject inventions throughout the
world. 
 3. DILIGENCE 
 BELLICUM shall:

 (i) Supply to BAYLOR an Annual Report within [...***...] of January 1st of each
year during the Term of the Agreement documenting Bellicum’s progress and activities related to research and development, securing regulatory approvals, manufacturing, sublicensing, marketing and sales of Licensed Product; 

(ii) File an investigational new drug (IND) application on a Licensed Product within [...***...] of the Agreement Date; 

(iii) Initiate a Phase III Clinical Trial on a Licensed Product within [...***...] of the Agreement Date; 

  
 ***Confidential
Treatment Requested 

  
 -5- 

 BAYLOR may [...***...] if BELLICUM does not perform (i), (ii) or (iii) in this section, subject to the
Term and Termination section (Section 10) herein. 
 4. PAYMENTS 

4.1 License Execution Fee. As partial consideration for the rights conveyed by BAYLOR under this Agreement, BELLICUM shall pay
BAYLOR a license fee of thirty thousand dollars ($30,000). Such payment shall be delivered to BAYLOR in installments according to the following schedule: 
  

	 	(i)	[...***...] dollars ($[...***...]) upon execution of this Agreement; 

  

	 	(ii)	[...***...] dollars ($[...***...]) due [...***...] from the Agreement Date; and 

  

	 	(iii)	[...***...] dollars ($[...***...]) due on [...***...]. 

 4.2 Annual Maintenance
Fee. BELLICUM shall pay to BAYLOR an annual maintenance fee of [...***...] dollars ($[...***...]) due upon each anniversary of the Agreement Date, beginning on the second anniversary of the Agreement Date and continuing until introduction of
a Licensed Product. 
 4.3 Royalty on Net Sales. BELLICUM will pay to BAYLOR a royalty of [...***...] percent
([...***...]%) of Net Sales of Licensed Product. Collectively the royalty payments that are the subject of this Paragraph 4.3 are termed “Royalties” for purposes of this Agreement and shall be payable as provided in Section 5. 

4.4 Minimum Royalties. Beginning with the calendar year following the first commercial sale of a Licensed Product, BELLICUM shall
pay to BAYLOR an amount such that the amount payable shall be the greater of: (i) the actual royalties on Net Sales of Licensed Products during the calendar year, or (ii) the following minimum royalties: 

(a) [...***...] dollars the first calendar year following the first commercial sale of a Licensed Product; 

(b) [...***...] dollars the second calendar year following the first commercial sale of a Licensed Product; 

(c) [...***...] dollars the third calendar year following the first commercial sale of a Licensed Product and thereafter. 

  
 ***Confidential
Treatment Requested 

  
 -6- 

 4.5 Milestones. BELLICUM shall also pay BAYLOR the following milestone payments set
forth below: 
 For the first (1st) clinical indication: 

 

			
	Phase I Clinical Trial Initiation	  	[...***...] ($[...***...])
		
	Phase II Clinical Trial Initiation	  	[...***...] dollars ($[...***...])
		
	For the first two (2) clinical indications:	  	
		
	Phase III Clinical Trial Initiation	  	[...***...] dollars ($[...***...])
		
	 First Regulatory Agency-Approved
 Commercial
Sale
	  	[...***...] dollars ($[...***...]).

 BELLICUM shall notify BAYLOR in writing within [...***...] days upon the achievement of each milestone, such
notice to be accompanied by payment of the appropriate milestone payment. Milestones are to be paid regardless of whether BELLICUM or BELLICUM’s sublicensee attains such milestone. 

4.6 Sublicense Revenue Sharing. In the event BELLICUM sublicenses the Subject Technology and Patent Rights under this Agreement,
BELLICUM agrees to pay to BAYLOR: 
 (i) [...***...] percent ([...***...]%) of Sublicense Revenue if the sublicense agreement is
executed on or before the [...***...]. 
 (ii) [...***...] percent ([...***...]%) of Sublicense Revenue shall be payable to Baylor if the
sublicense agreement is executed after the [...***...]. 
 4.7 Legal Costs. BELLICUM will be responsible for payment of all
Legal Costs, which BELLICUM will pay directly to each legal service provider on invoices for such legal costs received by BELLICUM. 

4.8 Failure to Make Payment. Should BELLICUM fail to make any payment whatsoever due and payable to BAYLOR hereunder, BAYLOR may,
at its sole option, terminate this Agreement as provided in Section 10. 
 5. REPORTING 

5.1 Notification of Sale of Licensed Products. BELLICUM shall notify BAYLOR the date on which BELLICUM and/or its sublicensee(s)
make a first sale of Licensed Products in each country in which it occurs within [...***...] days of occurrence. 
 5.2 Royalty
Reports. BELLICUM shall submit to BAYLOR within [...***...] after March 31, June 30, September 30 and December 31, a written report on a form provided by BAYLOR (a current version of which is attached as
Appendix A) setting forth for such calendar quarter at least the following information: 

  
 ***Confidential
Treatment Requested 

  
 -7- 

 (i) the number of Licensed Products sold by BELLICUM and sublicensees in each country; 

(ii) total billings for such Licensed Products; 

(iii) the gross amount of monies or cash equivalent or other consideration which is received for sales, leases, licenses or other modes of
transfer of Licensed Products by BELLICUM; 
 (iv) the identity of that consideration which is received instead of money for sales, leases,
licenses or other modes of transfer of Licensed Products by BELLICUM; 
 (v) allowed deductions from the gross amount as per Definition 1.7,
under which BELLICUM shall determine the amount of Net Sales thereof; 
 (vi) the amount of Royalties due thereon, or, if no Royalties are
due to BAYLOR for any reporting period, the statement that no Royalties are due; 
 (vii) the amount of Sublicensing Revenue received by
BELLICUM; and 
 (viii) the amount of other payments due BAYLOR, including but not limited to, milestone payments, minimum royalty payments
and maintenance fee payments. 
 The royalty report shall be certified as correct by an officer of BELLICUM. After termination or expiration of this
Agreement, BELLICUM will continue to submit royalty reports and payments to BAYLOR until all Licensed Products made, used, marketed, leased or imported under the Agreement have been sold. 

5.3 Payment to Accompany Royalty Report. BELLICUM shall pay to BAYLOR with each such royalty report the amount of
Royalties and other payments due with respect to such calendar quarter. If multiple technologies are covered by the license granted hereunder, BELLICUM shall specify which Subject Technology and Patent Rights are utilized for each Licensed Product
included in the royalty report by citing the applicable BLG number listed on the front page of the Agreement. 
 5.4
Payment Terms. All payments due hereunder are payable by check or wire transfer in United States dollars and shall be deemed received when the complete payment is credited to BAYLOR’s bank account. Until all funds are received by
BAYLOR, the payment by BELLICUM is not considered to be complete. For sales of Licensed Products in currencies other than the United States, BELLICUM shall use exchange rates published in [...***...] on the last business day of the calendar quarter
that such payment is due. No transfer, exchange, collection or other charges, including any wire transfer fees, shall be deducted from such payments. 

5.5 Late Payments. Late payments shall be subject to a charge of [...***...] percent ([...***...]%) per [...***...], the interest
being compounded annually, or [...***...] 

  
 ***Confidential
Treatment Requested 

  
 -8- 

 
dollars ($[...***...]), whichever is greater. BELLICUM shall calculate the correct late payment charge, and shall add it to each such late payment. Said late payment charge and the payment and
acceptance thereof shall not negate or waive the right of BAYLOR to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment. [...***...]. 

5.6 Payment Address: If payments are sent by check, they shall be sent to the address listed in Paragraph 14.1. If payments are
sent by wire transfer, they shall be sent using the wiring instructions sent by BAYLOR. 
 5.7 Notification of Merger or
Acquisition. In the event of acquisition, merger, change of corporate name, or change of make-up, organization, or identity, BELLICUM shall notify BAYLOR in writing within [...***...] days of such event. 

5.8 Small Entity Status Notification. If BELLICUM or sublicensee does not qualify as a “small entity” as provided by
the United States Patent and Trademark Office, BELLICUM will notify BAYLOR within [...***...] days of BELLICUM becoming aware of such entity status change. 

6. RECORDS AND INSPECTION 
 6.1
Obligation to Maintain Accounting Records. BELLICUM shall maintain, and shall cause its sublicensees to maintain, complete and accurate records relating to the rights and obligations under this Agreement and any amounts payable to BAYLOR
in relation to this Agreement, which records shall contain sufficient information to permit BAYLOR to confirm the accuracy of any reports delivered to BAYLOR and compliance in other respects with this Agreement. The relevant party shall retain such
records for at least five (5) years following the end of the calendar year to which they pertain. 
 6.2 BAYLOR Right to
Conduct Audit. During the Term of this Agreement as defined below and for a period of [...***...] thereafter, an independent certified public accountant, selected by BAYLOR and reasonably acceptable to BELLICUM (said acceptance shall not be
unreasonably withheld, delayed, or denied), shall have the right to inspect the books and records of BELLICUM in conjunction with the performance of BELLICUM’s obligations under the terms and conditions of this Agreement. BAYLOR will ensure
that the accountant will conduct the inspection in accordance with duties or confidentiality and non-use no less stringent than such provisions of this Agreement. Such inspection will pertain only to BELLICUM’s Sublicensing Revenue, Net Sales
and calculation of Royalties within the [...***...] period immediately preceding the start of the inspection, and BAYLOR’s accountant shall be granted access to records or documents required to determine the accuracy of any Sublicensing Revenue
payment, Net Sales calculation or Royalty payment. BELLICUM agrees to provide the accountant reasonable access to the records and documents, and shall cooperate reasonably with the accountant in support of its inspection and audit activities during
BELLICUM’s 

  
 ***Confidential
Treatment Requested 

  
 -9- 

 
normal business hours. The accountant will issue a report specifying the findings of its inspection and audit, and BAYLOR will immediately issue a copy of the report to BELLICUM. If either Party
disagrees with results of such report, BELLICUM and BAYLOR will use their good faith best efforts to resolve the disagreement. 
 6.3
Resolution of a Payment Deficiency. If a payment deficiency is determined, BELLICUM and its sublicensee(s), as applicable, shall pay the outstanding amounts within [...***...] days of receiving written notice thereof, plus interest on
such outstanding amounts as described in Section 5. 
 6.4 Responsibility for Audit Expenses. BAYLOR will pay for any
audit done under Paragraph 6.2. However, in the event that the audit reveals an underpayment of Royalties or fees by more than [...***...] percent ([...***...]%) for the period being audited, the cost of the audit shall be paid by BELLICUM. If the
underpayment is less than [...***...] percent ([...***...]%) but more than [...***...] percent ([...***...]%) for the period being audited, BELLICUM and BAYLOR shall [...***...] 

7. SUBLICENSES 
 All sublicenses
granted by BELLICUM of its rights hereunder shall have terms and conditions no less restrictive than those in this Agreement. BELLICUM shall be responsible for its sublicensees and shall not grant any rights which are inconsistent with the rights
granted to and obligations of BELLICUM hereunder. Should BELLICUM become aware of an act or omission of a sublicensee that would be a material breach of this Agreement, BELLICUM shall use reasonable business efforts to cause the sublicensee to cure
the breach. No such sublicense agreement shall contain a provision that illegally extends the term of Patent Rights under this Agreement. BELLICUM shall give BAYLOR prompt notification of the identity and address of each sublicensee with whom it
concludes a sublicense agreement and shall supply BAYLOR with a copy of each such sublicense agreement. 
 8. PATENTS AND INFRINGEMENT 

8.1 Patent Prosecution Responsibility. From the Agreement Date and for the term of this Agreement, BELLICUM shall have primary
responsibility, at its sole cost, to use patent counsel of its choice that is reasonably acceptable to BAYLOR for filing, prosecuting and maintaining all patent applications and patents included in the Patent Rights and Subject Technology licensed
hereunder, except that BAYLOR may assume responsibility at its sole expense for pursuing any protection which BELLICUM declines to prosecute pursuant to Paragraph 8.2 of this Agreement. 

8.2 Notification of Intent Not to Pursue. In the event that BELLICUM decides not to pay for the costs associated with either:
(i) the prosecution of patent applications in the Patent Rights or (ii) maintenance of any United States or foreign issued patent in the Patent Rights, BELLICUM shall provide BAYLOR [...***...] days written notice thereof. BELLICUM’s
right under this Agreement to practice an invention 

  
 ***Confidential
Treatment Requested 

  
 -10- 

 
validly claimed in an issued patent not pursued under this Section 8.2 shall terminate [...***...] days after such notice in the jurisdiction of the patent not pursued. 

8.3 Obligation to Inform. BELLICUM agrees to keep BAYLOR reasonably informed, at [...***...]’s expense, of prosecution and
other actions pursuant to this Section 8, including submitting to BAYLOR copies of all official actions and responses thereto. 

8.4 Obligation to Cooperate. BAYLOR agrees to reasonably cooperate with BELLICUM to whatever extent is reasonably necessary to
provide BELLICUM the full benefit of the license granted herein. 
 8.5 Infringement Procedures. During the term of this
Agreement, each Party shall promptly inform the other of any suspected infringement of any claims in the Patent Rights or the misuse, misappropriation, theft or breach of confidence of other proprietary rights in the Subject Technology and/or Patent
Rights by a third party, and with respect to such activities as are suspected. Any action or proceeding against such third party shall be instituted as follows: 

(i) BAYLOR and BELLICUM may agree to jointly institute an action for infringement, misuse, misappropriation, theft or breach of confidence of
the proprietary rights against such third party. Such joint action shall be brought in the names of both BAYLOR and BELLICUM. If BAYLOR or BELLICUM decide to jointly prosecute an action or proceeding after it has been instituted by one Party, the
action shall be continued in the name or names they both agree is expedient for efficient prosecution of such action. BELLICUM and BAYLOR shall agree to the manner in which they shall exercise control over any joint action or proceeding, providing
however that if they cannot agree BAYLOR shall have the right to unilaterally decide on control. In such joint action or proceeding, the out-of-pocket costs shall be borne equally, and any recovery or settlement shall be shared equally. 

(ii) If BELLICUM does not agree to participate in a joint action or proceeding then BAYLOR shall have the right, but not the obligation, to
institute an action for infringement, misuse, misappropriation, theft or breach of confidence of the proprietary rights against such third party. If BAYLOR elects to institute action, it does so at its own cost. If BAYLOR fails to bring such an
action or proceeding within a period of three (3) months after receiving notice or otherwise having knowledge of such infringement, then BELLICUM shall have the right, but not the obligation, to prosecute the same at its own expense. If
BELLICUM elects to institute action and action is not jointly instituted as described in Section 8.5(i), BELLICUM does so at its own cost and BAYLOR agrees to be named in the action and reasonably cooperate with costs of such actions by BAYLOR
being paid by BELLICUM. Should either BAYLOR or BELLICUM commence action under the provisions of this Paragraph 8.5 and thereafter elect to abandon the same, it shall give timely notice to the other Party who may, if it so desires, continue
prosecution of such action or proceeding. All recoveries, whether by 

  
 ***Confidential
Treatment Requested 

  
 -11- 

 
judgment, award, decree or settlement, from infringement or misuse of Subject Technology and/or Patent Rights shall be apportioned as follows: (a) the Party bringing the action or proceeding
shall first recover an amount equal the costs and expenses incurred by such Party directly related to the prosecution of such action or proceeding, (b) the Party cooperating in such action or proceeding shall then recover costs and expenses
incurred by such Party directly related to its cooperation in the prosecution of such action or proceeding and (c) the remainder will be divided proportionately between BAYLOR and BELLICUM according to the fraction of the costs and expenses
incurred by each Party. 
 8.6 Consent to Settle. Neither BAYLOR nor BELLICUM shall settle any action covered by Paragraph 8.5
without first obtaining the consent of the other Party, which consent will not be unreasonably withheld. 
 8.7 Liability for
Losses. BAYLOR shall not be liable for any losses incurred as the result of an action for infringement brought against BELLICUM as the result of BELLICUM’s exercise of any right granted under this Agreement. The decision to defend or
not defend shall be in BELLICUM’s sole discretion. 
 9. TERM AND EXPIRATION 

Unless sooner terminated as otherwise provided in Section 10, the license to employ Patent Rights and Subject Technology granted herein as part of
Section 2 shall expire on a country-by-country basis, on the date of expiration of the last of the Patent Rights to expire. After such expiration, BELLICUM shall have a perpetual, paid-in-full (i.e., royalty free) license in such country, 

10. TERMINATION 
 10.1
Termination by Baylor: Breach. In the event of default or failure by BELLICUM to perform any of the terms, covenants or provisions of this Agreement, BELLICUM shall have ninety (90) days after the receipt by BELLICUM of written
notice of such default by BAYLOR to correct such default. If such default is not corrected within the said ninety (90) day period, BAYLOR shall have the right, at its option, to cancel and terminate this Agreement. The Parties may mutually
agree, in writing, to extend the cure period for a default if BELLICUM has demonstrated good faith efforts to cure said default. However, BAYLOR is not obligated to grant such an extension. The failure of BAYLOR to exercise such right of termination
shall not be deemed to be a waiver of any right BAYLOR might have, nor shall such failure preclude BAYLOR from exercising or enforcing said right upon any subsequent failure by BELLICUM. 

10.2 Termination by Baylor: Insolvency. BAYLOR shall have the right, at its option, to cancel and terminate this Agreement in the
event that BELLICUM shall (i) become involved in insolvency, dissolution, bankruptcy or receivership proceedings affecting the operation of its business or (ii) make an assignment of all or substantially all of its assets for the benefit
of creditors, or in the event that (iii) a receiver or trustee is appointed for BELLICUM and BELLICUM shall, after the expiration of thirty (30) days following any of the events enumerated above, have been unable to secure a dismissal,
stay or other suspension of such proceedings. 

  
 -12- 

 10.3 Termination by Bellicum. BELLICUM, upon sixty (60) days prior written
notice to BAYLOR, may terminate this Agreement with or without cause. 
 10.4 Effects of Termination. In the event of
termination of this Agreement, all rights to the Subject Technology and Patent Rights shall revert to BAYLOR. 
 10.5
Termination: Sublicenses. Effective on the date of termination of this Agreement for any reason prior to expiration, BELLICUM hereby assigns to BAYLOR, and BAYLOR hereby accepts as a successor to BELLICUM, each authorized sublicense
agreement that is in effect on the date of termination. BELLICUM will notify, in writing, each sublicensee of such assignment within ten (10) days after the date of termination of this Agreement. BAYLOR will accept the assignment of each
sublicense agreement from BELLICUM when the sublicensee agrees in writing to be bound directly to BAYLOR by provisions of the sublicensing agreement. BELLICUM will include notification of this provision in this Section 10.5 in each sublicense
it grants under this Agreement. 
 10.6 No Refund. In the event this Agreement is terminated pursuant to this
Section 10, BAYLOR is under no obligation to refund any consideration made by BELLICUM to BAYLOR, as set forth in Section 4, prior to the effective date of such termination or expiration. 

10.7 Survival of Termination. No termination of this Agreement shall constitute a termination or a waiver of any rights of either
Party against the other Party accruing at or prior to the time of such termination. The obligations of Sections 4, 5, 6, 10, 12, 13, 14, 15, and 16 shall survive termination of this Agreement. 

11. ASSIGNMENT 

BELLICUM may assign this Agreement to a third party without BAYLOR’s approval or consent as part of: 

(i) A sale or other transfer of BELLICUM’s entire business; or 

(ii) A sale or other transfer of that part of BELLICUM’s business to which the license granted hereby relates; 

BELLICUM shall give BAYLOR [...***...] days prior written notice of such assignment, including the new contact information of assignee. In circumstances other
than (i) and (ii) of this Article 11, BELLICUM may assign this Agreement to a third party with the prior written consent of BAYLOR, which consent will not be unreasonably withheld, and BAYLOR will accept such assignment when the assignee
has agreed in writing to be 

  
 ***Confidential
Treatment Requested 

  
 -13- 

 
bound by terms of this Agreement. Upon such assignment of this Agreement by such assignee, the term “BELLICUM” as used herein (i) will include the name of the assignee should
BELLICUM assign a partial right and/or interest hereunder to the assignee, or (ii) will be replaced by the name of the assignee should BELLICUM assign its full right and interest hereunder to the assignee. 

12. GOVERNMENTAL COMPLIANCE 

12.1 Compliance with Laws. BELLICUM shall, during the term of this Agreement and for so long as it shall use the Subject
Technology or Patent Rights or sell Licensed Products, comply with and cause its sublicensees to comply with all laws that may control the import, export, manufacture, use, sale, marketing, distribution and other commercial exploitation of the
Subject Technology, Patent Rights, Licensed Products or any other activity undertaken pursuant to this Agreement. 
 12.2 Export
Control Regulations. The Subject Technology is subject to, and BELLICUM agrees to use commercially reasonable efforts to comply with, U.S. law including but not limited to U.S. export controls under the Export Administration Regulations (15
C.F.R. Part 734 et seq.) and U.S. economic sanctions and embargoes codified in 31 C.F.R. Chapter V. BELLICUM agrees that BELLICUM bears sole responsibility for understanding and complying with current U.S. trade controls laws and regulations as
applicable to its activities subject to this Agreement. Without limitation on the general agreement to comply set forth in the first sentence of this Paragraph 12.2, BELLICUM agrees not to sell any goods, services, or technologies subject to this
Agreement, or to re-export the same: (1) to any destination prohibited by U.S. law, including any destination subject to U.S. economic embargo; (2) to any end-user prohibited by U.S. law, including any person or entity listed on the U.S.
government’s Specially Designated Nationals list, Denied Parties List, Debarred Persons List, Unverified List, or Entities List. Furthermore, any transfer of Patent Rights from BAYLOR to BELLICUM under this Agreement may be subject to U.S.
export license authorization under U.S. law, and BAYLOR agrees to comply with applicable laws for such transfer. 
 12.3
Requirement for U.S. Manufacture. BAYLOR represents and certifies that research giving rise to the Patent Rights was partially funded by Federal funds, and that such Federal funds were solely from the National Institutes of Health (NIH).
BELLICUM agrees that Licensed Products developed as a result of such Federal funds and are leased or sold in the United States shall be manufactured substantially in the United States, unless a written waiver is obtained from the NIH. At the request
of BELLICUM, BAYLOR agrees to the best of its abilities to assist BELLICUM should BELLICUM seek such a waiver. 

  
 -14- 

 13. DISPUTE RESOLUTION  

13.1 Amicable Resolution. The parties shall attempt to settle any controversy between them amicably. To this end, a senior
executive from each Party shall consult and negotiate to reach a solution. The Parties agree that the period of amicable resolution shall toll any otherwise applicable statute of limitations. However, nothing in this clause shall preclude any
Party from commencing mediation if said negotiations do not result in a signed written settlement agreement within [...***...] days after written notice that these amicable resolution negotiations have commenced. 

13.2 Mediation. If a controversy arises out of or relates to this agreement, or the breach thereof, and if the controversy cannot
be settled through amicable resolution, the Parties agree to try in good faith to settle the controversy by mediation before resorting to final and binding arbitration. The Party seeking mediation shall propose five mediators, each of whom shall be
a lawyer licensed to practice by the state of Texas, having practiced actively in the field of commercial law for at least 15 years, to the other Party who shall select the mediator from the list. The Parties shall split the cost of the mediator
equally. The Parties agree that the period of mediation shall toll any otherwise applicable statute of limitations. However, nothing in this clause shall preclude any Party from commencing arbitration if said negotiations do not result in a signed
written settlement agreement within [...***...] days after written notice that amicable resolution negotiations have commenced. 

13.3 Arbitration. Any dispute, controversy, or claim arising out of or relating to this Agreement, or the breach, termination or
invalidity thereof, including claims for tortious interference or other tortious or statutory claims arising before, during or after termination, providing only that such claim touches upon matters covered by this Agreement shall be finally settled
by arbitration administered by the American Arbitration Association pursuant to the Commercial Arbitration Rules in force at the time of the commencement of the arbitration, except as modified by the specific provisions of this Agreement. It is the
specific intent of the Parties that this arbitration provision is intended to be the broadest form allowed by law. 
 13.4
Parties to Arbitration. This agreement to arbitrate is intended to be binding upon the signatories hereto, their principals, successors, assigns, subsidiaries and affiliates. This agreement to arbitrate is also intended to include any
disputes, controversy or claims against any Party’s employees, agents, representatives, or outside legal counsel arising out of or relating to matters covered by this Agreement or any agreement in which this Agreement is incorporated.

 13.5 Consolidation Permitted. The Parties expressly agree that any court with jurisdiction may order the consolidation
of any arbitrable controversy under this Agreement with any related arbitrable controversy not arising under this Agreement, as the court may deem necessary in the interests of justice or efficiency or on such other grounds as the court may deem
appropriate. 
 13.6 Entry of Judgment. The Parties agree that a final judgment on the arbitration award may be entered
by any court having jurisdiction thereof. 

  
 ***Confidential
Treatment Requested 

  
 -15- 

 13.7 Appointing Arbitrators. The American Arbitration Association shall appoint the
arbitrator(s) from its Large, Complex Claims Panel. If such appointment cannot be made from the Large, Complex Claims Panel, then from its Commercial Panel. The Parties hereby agree to and acquiesce in any appointment of an arbitrator or arbitrators
that may be made by such appointing authority. 
 13.8 Qualifications of the Arbitrator(s). The arbitrator(s) must be a lawyer,
having practiced actively in the field of commercial law for at least 15 years. 
 13.9 Governing Substantive Law. The
arbitrator(s) shall determine the rights and obligations of the Parties according to the substantive laws of the State of Texas (excluding conflicts of law principles) as though acting as a court of the State of Texas. 

13.10 Governing Arbitration Law. The law applicable to the validity of the arbitration clause, the conduct of the arbitration,
including any resort to a court for provisional remedies, the enforcement of any award and any other question of arbitration law or procedure shall be the Federal Arbitration Act. 

13.11 Governing Convention. The Parties elect to have the New York Convention on the Recognition and Enforcement of Foreign
Arbitral Awards of June 10, 1958 (instead of the Inter-American New York Convention on International Commercial Arbitration of August 15, 1990) govern any and all disputes that may be the subject of arbitration pursuant to this Agreement.

 13.12 Preliminary Issues of Law. The arbitrator(s) shall hear and determine any preliminary issue of law asserted by a Party
to be dispositive of any claim, in whole or part, in the manner of a court hearing a motion to dismiss for failure to state a claim or for summary judgment, pursuant to such terms and procedures as the arbitrator(s) deems appropriate. 

13.13 Confidentiality. The Parties and the arbitrator(s) shall treat all aspects of the arbitration proceedings, including
without limitation discovery, testimony and other evidence, briefs and the award, as strictly confidential. Further, except as may be required by law, neither Party nor the arbitrator(s) may disclose the existence, content, or results of any
arbitration hereunder without the prior written consent of both Parties. 
 13.14 Place of Arbitration. The seat of arbitration
shall be Houston, Texas, USA. 
 13.15 Language. The arbitration shall be conducted in the English language. All
submissions shall be made in English or with an English translation. Witnesses may provide testimony in a language other than English, provided that a simultaneous English translation is provided. Each Party shall bear its own translation costs.

  
 -16- 

 13.16 Punitive Damages Prohibited. The Parties hereby waive any claim to any
damages in the nature of punitive, exemplary, or statutory damages in excess of compensatory damages, or any form of damages in excess of compensatory damages, and the arbitrator(s) is/are specially divested of any power to award any damages
in the nature of punitive, exemplary, or statutory damages in excess of compensatory damages, or any form of damages in excess of compensatory damages. 

13.17 Costs. The Party prevailing on substantially all of its claims shall be entitled to recover its costs, including
attorneys’ fees, for the arbitration proceedings, as well as for any ancillary proceeding, including a proceeding to compel or enjoin arbitration, to request interim measures or to confirm or set aside an award. 

13.18 Survival. The provisions of this Section 13 shall survive expiration or termination of this Agreement. 

14. ADDRESSES 
 14.1 Baylor
Payment Address. All certificates of common stock shall be sent to the address below, and shall reference the applicable OTA numbers listed on the front page of the Agreement. 

BAYLOR Tax ID #: 74-1613878 

Baylor College of Medicine 

Licensing Group 
 P.O. Box 203710

 Houston, TX 77216-3710 

Telephone No. 713-798-6821 

Facsimile No. 713-798-1252 

E-Mail blg@bcm.tmc.edu 
 14.2
Bellicum Payment Address. For questions about payments, BAYLOR can contact BELLICUM at the address below: 
 Tom Farrell CEO 

Bellicum Pharmaceuticals, Inc. 

6400 Fannin Street, Suite 2300 

Houston, TX 77030 
 (713) 341-6472
direct 
 (713) 335-1446 fax 

(512) 507-0003 mobile 

tfarrell@bellicum.com 
 14.3
Address for Notices. All notices, reports or other communication pursuant to this Agreement shall be sent to such Party via (i) United States Postal Service postage prepaid, (ii) overnight courier, or (iii) facsimile
transmission, addressed 

  
 -17- 

 
to it at its address set forth below or as it shall designate by written notice given to the other Party. Notice shall be sufficiently made, or given and received (a) on the date of
mailing or (b) when a facsimile printer reflects transmission. 
 In the case of BAYLOR: 

Patrick Turley 
 Associate General
Counsel 
 Baylor College of Medicine 

One Baylor Plaza, BCM210-600D 

Houston, TX 77030 
 Telephone
No. 713-798-6821 
 Facsimile No. 713-798-1252 

E-Mail blg©bcm.tmc.edu 
 In
the case of BELLICUM: 
 Tom Farrell CEO 

Bellicum Pharmaceuticals, Inc. 

6400 Fannin Street, Suite 2300 

Houston, TX 77030 

(713) 341-6472 direct 

(713) 335-1446 fax 

(512) 507-0003 mobile 

tfarrell©bellicum.com 

14.4 Baylor Reference Number. Each such report, notice or other communication shall include the applicable Baylor reference
numbers listed on the front page of the Agreement. 
 15. REPRESENTATIONS, INDEMNITY & INSURANCE 

15.1 BELLICUM Representations. BELLICUM hereby represents and certifies that: 

(i) it is a corporation duly organized and in good standing under the laws of the State of Delaware; 

(ii) it is qualified to do business and in good standing in the State of Texas and elsewhere as the nature of its business and properties so
require; 
 (iii) the execution, delivery and performance of this Agreement by BELLICUM and the consideration provided for herein has been
duly authorized by corporate action; and 
 (iv) it has the full power and authority to enter into and carry out its obligations under this
Agreement. 

  
 -18- 

 BELLICUM agrees to indemnify and hold BAYLOR and its officers, trustees, faculty, employees, agents and
representatives, harmless from any liabilities, costs and expenses (including attorneys’ fees and expenses), obligations or causes of action arising out of or related to any breach of the representations and certifications made by BELLICUM in
this Section 15.1. 
 15.2 BAYLOR Representations. BAYLOR represents and certifies that: 

(i) it is qualified to do business and is in good standing in the State of Texas and elsewhere as the nature of its business and properties so
require; 
 (ii) the execution, delivery and performance of this Agreement by BAYLOR and the consideration provided for herein has been duly
authorized; 
 (iii) it has the full power and authority to enter into and carry out its obligations under this Agreement; and 

(iv) it controls the entire right, title and interest in the Patent Rights and the Subject Technology BAYLOR owns and is fully authorized to
make the grant in Section 2.1 of the Agreement. 
 15.3 GENERAL INDEMNITY. 

(I) EACH PARTY SHALL NOTIFY THE OTHER OF ANY CLAIM, LAWSUIT OR OTHER PROCEEDING RELATED TO THE SUBJECT TECHNOLOGY AND PATENT RIGHTS.
BELLICUM AGREES THAT IT WILL DEFEND, INDEMNIFY AND HOLD HARMLESS BAYLOR, ITS FACULTY MEMBERS, SCIENTISTS, RESEARCHERS, EMPLOYEES, OFFICERS, TRUSTEES AND AGENTS AND EACH OF THEM (THE “INDEMNIFIED PARTIES”), FROM AND AGAINST ANY AND ALL
CLAIMS, CAUSES OF ACTION, LAWSUITS OR OTHER PROCEEDINGS (THE “BAYLOR CLAIMS”) FILED OR OTHERWISE INSTITUTED AGAINST ANY OF THE INDEMNIFIED PARTIES ARISING OUT OF THE DESIGN, PROCESS, MANUFACTURE OR USE BY BELLICUM OF THE SUBJECT
TECHNOLOGY, PATENT RIGHTS, OR LICENSED PRODUCTS; PROVIDED, HOWEVER, THAT SUCH INDEMNITY SHALL NOT APPLY TO ANY CLAIMS ARISING FROM THE NEGLIGENCE OR INTENTIONAL MISCONDUCT OF ANY INDEMNIFIED PARTY. BELLICUM WILL ALSO ASSUME RESPONSIBILITY FOR ALL
COSTS AND EXPENSES RELATED TO SUCH CLAIMS FOR WHICH IT IS OBLIGATED TO INDEMNIFY THE INDEMNIFIED PARTIES PURSUANT TO THIS PARAGRAPH 15.3, INCLUDING, BUT NOT LIMITED TO, THE PAYMENT OF ALL REASONABLE ATTORNEYS’ FEES AND COSTS OF LITIGATION OR
OTHER DEFENSE. 
 (II) BELLICUM FURTHER AGREES NOT TO SETTLE ANY CLAIM AGAINST A BAYLOR INDEMNITEE WITHOUT THE INDEMNITEE’S
WRITTEN CONSENT WHICH CONSENT SHALL NOT BE UNREASONABLY WITHHELD. BELLICUM FURTHER AGREES TO KEEP BAYLOR INDEMNITEES FULLY APPRISED OF THE BAYLOR CLAIMS. 

  
 -19- 

 15.4 Insurance. 

(i) BELLICUM shall, for so long as BELLICUM manufactures, uses or sells any Licensed Product(s) for research applications, maintain in full force and effect
policies of (a) general liability insurance with limits of not less than [...***...] dollars ($[...***...]) per occurrence with an annual aggregate of [...***...] dollars ($[...***...]) and (b) products liability insurance, with limits of
not less than [...***...] dollars ($[...***...]) per occurrence with an annual aggregate of [...***...] dollars ($[...***...]). 
 (ii) BELLICUM shall
provide to BAYLOR copies of certificates of insurance or copies of the policies of insurance within [...***...] days after BELLICUM receives a request from BAYLOR for such copies. It is the intention of the Parties hereto that BELLICUM shall,
throughout the term of this Agreement, continuously and without interruption, maintain in force the required insurance coverages set forth in this Paragraph 15.4. 

(iii) BAYLOR reserves the right to request additional policies of insurance where appropriate and reasonable in light of BELLICUM’s business operations
and availability of coverage. 
 15.5 DISCLAIMER OF WARRANTY. BAYLOR MAKES NO WARRANTIES OR REPRESENTATIONS OTHER THAN THOSE
MADE ABOVE, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF FITNESS OR MERCHANTABILITY, REGARDING OR WITH RESPECT TO THE SUBJECT TECHNOLOGY, PATENT RIGHTS OR LICENSED PRODUCTS AND BAYLOR MAKES NO WARRANTIES OR REPRESENTATIONS,
EXPRESS OR IMPLIED, OF THE PATENTABILITY OF THE SUBJECT TECHNOLOGY, PATENT RIGHTS OR LICENSED PRODUCTS OR OF THE ENFORCEABILITY OF ANY PATENTS ISSUING THEREUPON, IF ANY, OR THAT THE SUBJECT TECHNOLOGY, PATENT RIGHTS OR LICENSED PRODUCTS ARE OR SHALL
BE FREE FROM INFRINGEMENT OF ANY PATENT OR OTHER RIGHTS OF THIRD PARTIES. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS UNDER ANY PATENTS OF BAYLOR OTHER THAN THE PATENT
RIGHTS, REGARDLESS OF WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS. 
 16. ADDITIONAL PROVISIONS 

16.1 Use of BAYLOR Name. BAYLOR agrees that BELLICUM may publicly disclose the existence of this Agreement, the name “Baylor
College of Medicine” and the names of scientists and researchers at BAYLOR associated with the Patent Rights and Technology Rights. BELLICUM will not disclose it has an affiliation with BAYLOR that does not exist at the time the name
“Baylor College of Medicine” is publicly disclosed. 

  
 ***Confidential
Treatment Requested 

  
 -20- 

 16.2 Confidentiality. 

(i) Confidential Information will be marked “CONFIDENTIAL.” The recipient of Confidential Information (“Recipient”) agrees to retain in
confidence and to prevent the disclosure of the Confidential Information from the discloser (“Discloser”) to any third party without the prior written consent of the Discloser; provided, however, the Recipient may disclose Confidential
Information to its officers, directors, employees, partners, investors, shareholders, lawyers, accountants, and consultants (collectively, the “Representatives”) on a need-to-know basis only for the purpose of assisting the Recipient in
evaluating the Confidential Information or in the discharge of its obligations under this Agreement. The Recipient will use the same degree of care with respect to the Confidential Information as it would with its own proprietary and confidential
information, and in no event use less than a reasonable degree of care. The Recipient will use reasonable efforts to notify its Representatives about the Recipient’s duties under this Agreement and to promote Representatives’ maintenance
of the confidentiality of the Confidential Information as if the Representatives were themselves parties to this Agreement. BELLICUM may disclose Confidential Information to potential licensees, purchasers, investors, joint venturers and the like so
long as BELLICUM uses commercially reasonable efforts to make such disclosures subject to a confidentiality agreement. The Recipient agrees to retain in confidence and to prevent the disclosure of any document prepared by or for the Recipient that
includes Discloser’s Confidential Information, including without limitation any document that analyzes or summarizes Discloser’s Confidential Information, to any third party without the prior written consent of the Discloser. 

(ii) This Agreement imposes no obligations upon the Recipient with respect to any Confidential Information which (a) was in the Recipient’s
possession before receipt of such information from the Discloser, as evidenced by competent written proof; (b) is or becomes a matter of public knowledge through no fault or violation of this Agreement by the Recipient or its Representatives;
(c) is rightfully received by the Recipient from a third party who, to the Recipient’s knowledge, is not under a duty of confidentiality; (d) is approved in writing for release by the Discloser prior to such release; (e) is
independently developed by the Recipient as evidenced by Recipient’s written records without any use of or reference to Confidential Information of the Discloser; or (f) is disclosed in an intangible medium (e.g., visual, oral) and not
confirmed in a writing to the Recipient within thirty (30) days after its initial disclosure by the Discloser. Notwithstanding any other provision of this Agreement, the Recipient may disclose Confidential Information which is required to be
disclosed by law, rule, regulation, administrative, or legal process (“Compelled Request”); provided, however, the Recipient will give prompt written notice of any Compelled Request for such information to the Discloser and agrees to
cooperate with the Discloser, at the Discloser’s expense, to challenge the request or limit the scope of disclosure of such information, as the Discloser may request and deem appropriate. 

  
 -21- 

 (iii) Each Party agrees to notify the other Party in writing of any misuse or misappropriation of the other
Party’s Confidential Information that may come to its attention. The Parties hereby acknowledge and agree that in the event of any breach of this Section 16.2, including, without limitation, the actual or threatened disclosure or
unauthorized use of Confidential Information without the prior express written consent of the Discloser, the Discloser would suffer an irreparable injury such that no remedy at law would adequately protect or appropriately compensate the disclosing
party for such injury. Accordingly, the Parties agree that the Discloser will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond or further showing and
without prejudice to any other rights and remedies that the Discloser may have for a breach of this Section 16.2. 
 16.3 No
Additional Rights. BELLICUM acknowledges that, other than the specific rights granted hereunder, it is not entitled to any rights to any current or future technology, research or developments made at or owned by BAYLOR. 

16.4 BAYLOR’s Disclaimers. Neither BAYLOR, nor any of its faculty members, scientists, researchers, employees, officers,
trustees or agents assume any responsibility for the manufacture, product specifications, sale or use of the Subject Technology or the Licensed Products which are manufactured by or sold by BELLICUM. 

16.5 Independent Contractors. The Parties hereby acknowledge and agree that each is an independent contractor and that neither
Party shall be considered to be the agent, representative, master or servant of the other Party for any purpose whatsoever, and that neither Party has any authority to enter into a contract, to assume any obligation or to give warranties or
representations on behalf of the other Party. Nothing in this relationship shall be construed to create a relationship of joint venture, partnership, fiduciary or other similar relationship between the Parties. 

16.6 Non-Waiver. The Parties covenant and agree that if a Party fails or neglects for any reason to take advantage of any of the
terms provided for the termination of this Agreement or if a Party, having the right to declare this Agreement terminated, shall fail to do so, any such failure or neglect by such Party shall not be a waiver or be deemed or be construed to be a
waiver of any cause for the termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants or conditions of this Agreement or of the performance thereof. None of the terms, covenants and conditions of this
Agreement may be waived by a Party except by its written consent. 
 16.7 Reformation. The Parties hereby agree that
neither Party intends to violate any public policy, statutory or common law, rule, regulation, treaty or decision of any government agency or executive body thereof of any country or community or association of countries, and that if any word,
sentence, paragraph or clause or combination thereof of this Agreement is found, by a court or executive body with judicial powers having jurisdiction over this Agreement or any of the Parties hereto, in a final, unappealable order to be in
violation of any such provision in any country or 

  
 -22- 

 
community or association of countries, such words, sentences, paragraphs or clauses or combination shall be inoperative in such country or community or association of countries, and the
remainder of this Agreement shall remain binding upon the Parties hereto. 
 16.8 Force Majeure. No liability hereunder
shall result to a Party by reason of delay in performance caused by force majeure, that is circumstances beyond the reasonable control of the Party, including, without limitation, acts of God, fire, flood, war, terrorism, civil unrest, labor unrest,
or shortage of or inability to obtain material or equipment. 
 16.9 Informed Review. Each Party acknowledges that it
and its counsel have received and reviewed this Agreement and that normal rules of construction, to the effect that ambiguities are to be resolved against the drafting Party, shall not apply to this Agreement or to any amendments, modifications,
exhibits or attachments to this Agreement. 
 16.10 Section Headings. The section headings used in this Agreement are
intended for purposes of reference and convenience only, and shall not enter into any interpretation of this Agreement. 
 16.11
Entire Agreement. The terms and conditions herein constitute the entire agreement between the Parties and shall supersede all previous agreements, either oral or written, between the Parties hereto with respect to the subject matter
hereof. No agreement of understanding bearing on this Agreement shall be binding upon either Party hereto unless it shall be in writing and signed by the duly authorized officer or representative of each of the Parties and shall expressly refer to
this Agreement. 
 IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple originals by their
duly authorized officers and representatives on the respective dates shown below, but effective as of the Agreement Date. 
  

									
	BELLICUM PHARMACEUTICALS, INC.	 		 	BAYLOR COLLEGE OF MEDICINE
					
	Name:	 	 /s/ Thomas J. Farrell
	 		 	Name:	 	 /s/ Illegible

		 	Thomas J. Farrell	 		 		 	
					
	Title:	 	Chief Executive Officer	 		 	Title:	 	Sr. VP and Dean of Research
					
	Date:	 	June 27, 2010	 		 	Date:	 	June 22, 2010

  

	
	 APPROVED AS TO FORM
 Office of the General
Counsel
 Baylor College of Medicine
 By: /s/
6/17/10

  
 -23- 

 Appendix A 

Royalty Report 
  

									
	BLG #:	  	  
	  		  		  	
	Licensee:	  	  
	  		  		  	
	Reporting Period:      	  	  
	  		  		  	
	Prepared By	  	  
	  	Date:	  	  
	  	
	Approved By	  	  
	  	Date:	  	  
	  	

 Please prepare a separate report for each product line. Then combine all product lines into a summary report. 

Product Line Code
(SKU):                                        
              
  

																			
	Country	 	
    Units    

Sold
	 	
    Exchange    

Rate
	 	
Total

    Billings    

(USD)
	 	
    Gross    

Sales
 (USD)
	 	
Less

    Deductions*    

(USD)
	 	 Net

Sales

    (USD)    
	 	
    Royalty    

Rate
	 	 Royalty

    Amount    
	 
	 USA
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Canada
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Europe:  
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Japan
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Other:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Total
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	            	  
	 Third Party Royalty Payments
(USD)
	 	$	            	  
	 Net Royalty Payable
(USD)
	 	$	            	  
	
Sublicensing             Revenue

(USD)
	 	$	            	  
	 Other Payments- Milestones,
Minimum Royalties, Maintenance Fees (USD)
	 	$	            	  
	 	 	 	 	 
	 Total Payment Due
(USD)
	 	$	            	  

  

	*	Deduction Description: 

  
 -24-EX-10.19

 Exhibit 10.19 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
  

 
 STATE OF TEXAS 
 COUNTY OF
TRAVIS 
 This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of
Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Executive Director, and Bellicum Pharmaceuticals, Inc., hereinafter referred to as the
“RECIPIENT”, acting through its authorized signing official. 
 RECITALS 

WHEREAS, pursuant to TEX. HEALTH & SAFETY CODE, Ch. 102, the INSTITUTE may make grants to
public and private persons in this state for research into the causes and cures for all types of cancer in humans; facilities for use in research into the causes and cures for cancer; research to develop therapies, protocols, medical
pharmaceuticals, or procedures for the cure or substantial mitigation of all types of cancer; and cancer prevention and control programs. 
 WHEREAS,
Article III, Section 67 of the Texas Constitution expressly authorizes the State of Texas to sell general obligation bonds on behalf of the INSTITUTE and for the INSTITUTE to use the proceeds from the sale of the bonds for the purposes of
cancer research and prevention programs in this state. 
 WHEREAS, the INSTITUTE issued a request for applications for RFA R-11-COMP-1: Company
Commercialization Awards on or about July 2010. 
 WHEREAS, pursuant to TEX. HEALTH & SAFETY CODE § 102.251, and after a review by the
INSTITUTE’s scientific research and prevention program committees, the INSTITUTE’s Executive Director has approved a Grant (defined below) to be awarded to the RECIPIENT. 

WHEREAS, to ensure that the Grant provided to the RECIPIENT pursuant to this Contract is utilized in a manner consistent with Tex. Const. Article III,
Section 67 and other laws, and in exchange for receiving such Grant, the RECIPIENT agrees to comply with certain conditions and deliver certain performance. 

WHEREAS, the RECIPIENT and the INSTITUTE desire to set forth herein the provisions relating to the awarding of such monies and the disbursement thereof to the
RECIPIENT. 
 IN CONSIDERATION of the Grant and the premises, covenants, agreements, and provisions contained in this Contract, the parties agree to
the following terms and conditions: 

  
 1 

 Article I 

DEFINITIONS 
 The following terms shall
have the following meaning throughout this Contract and any Attachments and amendments. Other terms may be defined elsewhere in this Contract. 
 (1)
Collaborator – any entity other than the RECIPIENT having one or more personnel participating in the Project and (a) designated as a collaborator in the application submitted by the RECIPIENT requesting the Grant funds
awarded by the INSTITUTE, or (b) otherwise approved in writing as a collaborator by the INSTITUTE. 
 (2) Contractor – any person or
entity, other than a Collaborator or the RECIPIENT (or their respective personnel), who is contracted by the RECIPIENT to perform activities for the Project. 

(3) Equipment  –  an article of tangible, nonexpendable personal property having a useful life of more than one year
and an acquisition cost of $5,000 or more per unit. 
 (4) Grant – the funding assistance authorized by TEX. HEALTH & SAFETY
CODE, Ch. 102 in the amount specified in Section 2.01 and awarded by the INSTITUTE to the RECIPIENT to carry out the Project pursuant to the terms and conditions of this Contract. 

(5) Indirect Costs – the expenses of doing business that are not readily identified with a particular grant, contract, project, function or
activity, but are necessary for the general operation of the organization or the performance of the organization’s activities. 
  

	(6)	Institute-Funded Activity – all aspects of work conducted on or as part of the Project. 

(7) Non-Profit Organization – a university or other institution of higher education or an organization of the type described in 501(c)(3)
of the Internal Revenue Code of 1986, as amended (26 U.S.C. 501 (c)(3)) and exempt from taxation under 501 (a) of the Internal Revenue Code (26 U.S.C. 501 (a)) or any nonprofit scientific or educational organization qualified under a state
nonprofit organization statute. 
 (8) Principal Investigator/Program Director – the individual designated by the RECIPIENT to direct the
Project who is principally responsible and accountable to the RECIPIENT and the INSTITUTE for the proper conduct of the Project. References herein to “Principal Investigator/Program Director” include Co-Principal Investigators or
Co-Program Directors as well. The Principal Investigator/Program Director and Co-Principal Investigators or Co-Program Directors are set forth on Attachment A. 

(9) Project – the activities specified or generally described in the Scope of Work or otherwise in this Contract (including without
limitation any of the Attachments to the Contract) that are approved by the INSTITUTE for funding, regardless of whether the INSTITUTE funding constitutes all or only a portion of the financial support necessary to carry them out. 

(10) Recipient Personnel – The RECIPIENT’s Principal Investigator/Program Director and RECIPIENT’s employees and consultants
working on the Project. 

  
 2 

 Article II 

GRANT AWARD 
 Section 2.01 Award of
Monies. In accordance with the provisions of this Contract, the INSTITUTE shall disburse the proceeds of the Grant to the RECIPIENT in an amount not to exceed $5,680,310 to be used solely for the Project. This award is subject to
compliance with the Scope of Work and demonstration of progress towards achievement of the milestones set forth in Section 2.02. The INSTITUTE, in its sole discretion, may award supplemental funding not to exceed ten percent (10%) of the
total Grant amount based upon progress made by the RECIPIENT pursuant to the Scope of Work. This Grant is not intended to be a loan of money. 

Section 2.02 Scope of Work and Milestones. The RECIPIENT shall perform the Project in accordance with this Agreement and as outlined in
Application RP110508 submitted by the RECIPIENT and approved by the INSTITUTE. The RECIPIENT shall conduct the Project within the State of Texas with Texas-based employees, Contractors and/or Collaborators unless otherwise specified in the
Scope of Work or the Approved Budget. The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment A in their entirety, incorporate them as if fully set forth herein, and agree that the Project description, goals, timeline and milestones
included as Attachment A accurately reflect the Scope of Work of the Project to be undertaken by the RECIPIENT (the “Scope of Work”) and the milestones expected to be achieved. RECIPENT and the INSTITUTE mutually agree that
the outcome of scientific research is unpredictable and cannot be guaranteed. The RECIPIENT shall use commercially reasonable efforts to complete the goals of the Project pursuant to the timeline reflected in Attachment A and shall timely notify the
INSTITUTE if circumstances occur that materially and adversely affect completion thereof. Modifications, if any, to the Scope of Work must be agreed to in writing by both parties as set forth in Section 2.06 “Amendments and
Modifications” herein. Material changes to the Scope of Work include, but are not limited to, changes in key personnel involved with the Project, the site of the Project, and the milestones expected to be achieved. 

Section 2.03 Contract Term. The Contract shall be effective as of June 1, 2011 (the “Effective Date”) and
terminate on May 31, 2013 or in accordance with the Contract termination provisions set forth in Article VIII herein, whichever shall occur first (the “Termination Date”). Unless otherwise approved by the
INSTITUTE as evidenced by written communication from the INSTITUTE to the RECIPIENT and appended to the Contract, Grant funds distributed pursuant to the Contract shall be expended no earlier than the Effective Date or subsequent to the Termination
Date. If, as of the Termination Date, the RECIPIENT has not used Grant money awarded by the INSTITUTE for permissible services, expenses, or costs related to the Project and has not received approval from the INSTITUTE for a no cost extension to the
contract term pursuant to Section 3.11 “Carry Forward of Unspent Funds and No Cost Extension” herein, then the RECIPIENT shall not be entitled to retain such unused Grant funds from the INSTITUTE. Certain obligations as set forth in
Section 9.09 of this Contract shall extend beyond the Termination Date. 
 Section 2.04 Contract Documentation. The Contract between the
INSTITUTE and the RECIPIENT shall consist of this final, executed Contract, including the following Attachments to the Contract, all of which are hereby incorporated by reference: 

 

	 	(a)	Attachment A – Project Description, Goals and Timeline 

  
 3 

	 	(b)	Attachment B – Approved Budget, including changes approved by the INSTITUTE subsequent to execution of the Contract. 

  

	 	(c)	Attachment C – Assurances and Certifications 

  

	 	(d)	Attachment D – Intellectual Property and Revenue Sharing 

  

	 	(e)	Attachment E – Reporting Requirements 

  

	 	(f)	Attachment F – Approved Amendments to Contract, excluding budget amendments reflected in Attachment B. 

Section 2.05 Entire Agreement. All agreements, covenants, representations, certifications and understandings between the parties hereto concerning
this Contract have been merged into this written Contract. No prior or contemporaneous representation, agreement or understanding, express or implied, oral or otherwise, of the parties or their agents that may have related to the subject matter
hereof in any way shall be valid or enforceable unless embodied in this Contract. 
 Section 2.06 Amendments and Modifications. Requested
amendments and modifications to the Contract must be submitted in writing to the INSTITUTE for review and approval (such approval shall not be unreasonably withheld.) Amendments and modifications (including alterations, additions, deletions,
assignments and extensions) to the terms of this Contract shall be made solely in writing and shall be executed by both parties. The approved amendment shall be reflected in Attachment A if it is change to the Scope of Work, or as part of Attachment
B if it is a budget amendment, or as part of Attachment F for all other changes. No handwritten changes to this Contract shall be effective unless initialed and dated by authorized signatories of both parties. 

Section 2.07 Relationship of the Parties. The RECIPIENT shall be responsible for the conduct of the Project that is the subject of this Contract
and shall direct the activities and at all times be responsible for the performance of Recipient Personnel, Collaborators, Contractors and other agents. The INSTITUTE does not assume responsibility for the conduct of the Project or any
Institute-Funded Activity that is the subject of this Contract. The INSTITUTE and the RECIPIENT shall perform their respective obligations under this Contract as independent contractors and not as agents, employees, partners, joint venturers, or
representatives of the other party. Neither party is permitted to make representations or commitments that bind the other party. 
 Section 2.08
Subcontracting. Any and all subcontracts entered into by the RECIPIENT in relation to the performance of activities under the Project shall be in writing and shall be subject to the requirements of this Contract. Without in any way limiting the
foregoing, the RECIPIENT shall enter into and maintain a written agreement with each such permitted Contractor with terms and conditions sufficient to ensure the RECIPIENT fully complies with the terms of this Contract, including without limitation
the terms set forth in Attachments C, D, and E. The RECIPIENT agrees that it shall be responsible to the INSTITUTE for the performance of and payment to any Contractor. Any reimbursements made by the RECIPIENT to a Contractor shall be made in
accordance with the applicable provisions of TEX. GOV’T. CODE, Ch. 2251. 

  
 4 

 Section 2.09 Transfer or Assignment by the Recipient. This Contract is not transferable or otherwise
assignable by the RECIPIENT, whether by operation of law or otherwise, without the prior written consent of the INSTITUTE, except as provided in this Section 2.09. Any such attempted transfer or assignment without the prior written consent of
the INSTITUTE (except as provided in this Section 2.09) shall be null, void and of no effect. For purposes of this section, an assignment or transfer of this Contract by the RECIPIENT in connection with a merger, transfer or sale of all or
substantially all of the RECIPIENT’s assets or business related to this Contract or a consolidation, change of control or similar transaction involving the RECIPIENT shall not be deemed to constitute a transfer or assignment, so long as such
action does not impair or otherwise negatively impact the revenue sharing terms in Attachment D. Nothing herein shall be interpreted as superseding the requirement that the Project be undertaken in Texas with Texas-based employees. 

If the Principal Investigator leaves the employment of the RECIPIENT or is replaced by the RECIPIENT for any reason during the course of the Grant with
someone who is not already designated a co-Principal Investigator in Attachment A, the RECIPIENT shall notify the INSTITUTE prior to replacing the Principal Investigator. Written approval by the INSTITUTE is required for the replacement of the
Principal Investigator with someone who is not already a co-Principal Investigator in Attachment A, which approval shall not be unreasonably withheld, conditioned or delayed. 

Section 2.10 Representations and Certifications. The RECIPIENT represents and certifies to the best of its knowledge and belief to the INSTITUTE
as follows: 
  

	 	(a)	It has legal authority to enter into, execute, and deliver this Contract, and all documents referred to herein, and it has taken all corporate actions necessary to its execution and delivery of such documents;

  

	 	(b)	It will comply with all of the terms, conditions, provisions, covenants, requirements, and certifications in this Contract, and all other documents incorporated herein by reference; 

 

	 	(c)	It has made no material false statement or misstatement of fact in connection with this Contract and its receipt of the Grant, and all of the information it previously submitted to the INSTITUTE or that it is required
under this Contract to submit to the INSTITUTE relating to the Grant or the disbursement of any of the Grant is and will be true and correct at the time such statement is made; 

 

	 	(d)	It is in compliance in all material respects with provisions of its charter and of the laws of the State of Texas, and of the laws of the jurisdiction in which it was formed, and (i) there are no actions, suits, or
proceedings pending, or threatened, before any judicial body or governmental authority against or affecting its ability to enter into this Contract, or any document referred to herein, or to perform any of the material acts required of it in such
documents and (ii) it is not in default with respect to any order, writ, injunction, decree, or demand of any court or any governmental authority which would impair its ability to enter into this Contract, or any document referred to herein, or
to perform any of the material acts required of it in such documents; 

  

	 	(e)	Neither the execution and delivery of this Contract or any document referred to herein, nor compliance with any of the terms, conditions, requirements, or provisions contained in this Contract or any documents referred
to herein, is prevented by, is a breach of, or will result in a breach of, any term, condition, or provision of any agreement or document to which it is now a party or by which it is bound; and 

  
 5 

	 	(f)	It shall furnish such satisfactory evidence regarding the representations and certifications described herein as may be required and requested by the INSTITUTE from time to time. 

Section 2.11 Reliance upon Representations. By awarding the Grant and executing this Contract, the INSTITUTE is relying, and will continue to rely
throughout the term of this Contract, upon the truthfulness, accuracy, and completeness of the RECIPIENT’s written assurances, certifications and representations. Moreover, the INSTITUTE would not have entered into this Contract with the
RECIPIENT but for such written assurances, certifications and representations. The RECIPIENT acknowledges that the INSTITUTE is relying upon such assurances, certifications and representations and acknowledges their materiality and significance.

 Section 2.12 Contingent upon Availability of Grant Funds. This Contract is contingent upon funding being available for the term of the
Contract and the RECIPIENT shall have no right of action against the INSTITUTE in the event that the INSTITUTE is unable to perform its obligations under this Contract as a result of the suspension, termination, withdrawal, or failure of funding to
the INSTITUTE or lack of sufficient funding of the INSTITUTE for this Contract. If funds become unavailable to the INSTITUTE during the term of the Contract, Section 8.01(c) shall apply. For the sake of clarity, and except as otherwise provided
by this Contract, if this Contract is not funded, then both parties are relieved of all of their obligations under this Contract. The INSTITUTE acknowledges and agrees that the Project is a multiyear project subject to Tex. Health & Safety
Code, Chr. 102, Section 102.257. 
 Section 2.13 Confidentiality of Documents and Information. In connection with work contemplated for the
Project or pursuant to complying with various provisions of this Contract, the RECIPIENT may disclose its confidential business, financial, technical, scientific information and other information to the INSTITUTE (“Confidential
Information”). To assist the INSTITUTE in identifying such information, the RECIPIENT shall mark or designate the information as “confidential,” provided however that the failure to so designate does not operate as a waiver to
protections provided by applicable law or this Contract. The INSTITUTE shall use no less than reasonable care to protect the confidentiality of the Confidential Information to the fullest extent permissible under the Texas Public Information Act,
Texas Government Code, Chapter 552 (the “TPIA”), and, except as otherwise provided in the TPIA to prevent the disclosure of the Confidential Information to third parties for a period of time equal to three (3) years from
the termination of the contract, unless the INSTITUTE and the RECIPIENT agree in writing to extend such time period, provided that this obligation shall not apply to information that: 

 

	 	(a)	was in the public domain at the time of disclosure or later became part of the public domain through no act or omission of the INSTITUTE in breach of this Contract; 

 

	 	(b)	was lawfully disclosed to the INSTITUTE by a third party having the right to disclose it without an obligation of confidentiality; 

  

	 	(c)	was already lawfully known to the INSTITUTE without an obligation of confidentiality at the time of disclosure; 

  

	 	(d)	was independently developed by the INSTITUTE without using or referring to the RECIPIENT’s Confidential Information; or 

  

	 	(e)	is required by law or regulation to be disclosed. 

  

  
 6 

 The INSTITUTE shall hold the Confidential Information in confidence, shall not use such Confidential Information
except as provided by the terms of this Contract, and shall not disclose such Confidential Information to third parties without the prior written approval of the RECIPIENT or as otherwise allowed by the terms of the Contract. Subject in all respects
to the terms of this Contract and the TPIA, the INSTITUTE has the right to use and disclose the Confidential Information reasonably in connection with the exercise of its rights under the Contract. 

In the event that the INSTITUTE is requested or required (by oral questions, interrogatories, requests for information or documents in legal proceedings,
subpoena, civil investigative demand or other similar process by a court of competent jurisdiction or by any administrative, legislative, regulatory or self- regulatory authority or entity) to disclose any Confidential Information, the INSTITUTE
shall provide the RECIPIENT with prompt written notice of any such request or requirement so that the RECIPIENT may seek a protective order or other appropriate remedy. If, in the absence of a protective order or other remedy, the INSTITUTE is
nonetheless legally compelled to make any such disclosure of Confidential Information to any person, the INSTITUTE may, without liability hereunder, disclose only that portion of the Confidential Information that is legally required to be disclosed,
provided that the INSTITUTE will use reasonable efforts to assist the RECIPIENT, at the RECIPIENT’s expense, in obtaining an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Confidential
Information. To the extent that such Confidential Information does not become part of the public domain by virtue of such disclosure, it shall remain Confidential Information hereunder. 

Article III 

DISBURSEMENT OF GRANT AWARD PROCEEDS 

Section 3.01 Payment of Grant Award Proceeds. The INSTITUTE will advance Grant award proceeds upon request by the RECIPIENT, consistent with the
amounts and schedule as provided in Attachment B. If the RECIPIENT does not request advancement of funds for some or all of the Grant award proceeds, disbursement of Grant award proceeds for services performed and allowable expenses and costs
incurred pursuant to the Scope of Work will be on a reimbursement basis. 
 Section 3.02 Requests for Reimbursement and Quarterly Financial Status
Reports. If the RECIPIENT does not elect to receive an advance disbursement of Grant proceeds, the RECIPIENT’s requests for reimbursement shall be made on INSTITUTE Form 269a (Financial Status Report). If the RECIPIENT has elected to
receive an advance disbursement of Grant proceeds, RECIPIENT shall submit INSTITUTE Form 269a (Financial Status Report) to document all costs and allowable expenses paid with Grant proceeds. The RECIPIENT shall submit the INSTITUTE Form 269a
quarterly to the INSTITUTE within 90 days following the end of the quarter covered by the bill. A final INSTITUTE Form 269a shall be submitted by RECIPIENT not later than 90 days after the Termination Date. An extension of time for submission
deadlines specified herein must be expressly authorized in writing by the INSTITUTE. 
 Section 3.03 Actual Costs and Allowable Expenses.
Because the Approved budget for the Project(s) as set forth in Attachment B is only an estimate, the parties agree that the RECIPIENT’s billings under this Contract will reflect the actual costs and expenses incurred in performing the
Project(s), regardless of the Approved Budget, up to the total contracted amount specified in Section 2.01 “Award of Monies.” The RECIPIENT shall use Grant proceeds only for allowable expenses consistent with state law and agency
administrative rules. Allowable expenses for the Project(s) shall be only as outlined in the Approved Budget and any modifications to same. 

  
 7 

 Section 3.04 Travel Expenses. Reimbursement for travel expenditures shall be in accordance with the
Approved Budget. Prior written approval from the INSTITUTE must be obtained before travel that exceeds the amount included in the Approved Budget commences. Failure to obtain such prior written approval shall result in such excess travel costs
constituting expenses that may not be taken into account for the purposes of calculating expenditure of Grant funds under this Contract. 

Section 3.05 Budget Modifications. The total Approved Budget and the assignment of costs may be adjusted based on implementation of the Scope of
Work, spending patterns, and unexpended funds, but only by an amendment to the Approved Budget. In no event shall an amendment to the Approved Budget result in payments in excess of the aggregate amount specified in Section 2.01 “Award of
Monies” or in approved supplemental funding for the Project, if any. The RECIPIENT may make transfers between or among lines within budget categories without prior written approval provided that: 

 

	 	(a)	The total dollar amount of all changes of any single line item within budget categories (individually and in the aggregate) is less than [...***...]% of the total Approved Budget; 

 

	 	(b)	The transfer will not increase or decrease the total Approved Budget; 

  

	 	(c)	The transfer will not materially change the nature, performance level, or Scope of Work of the Project; and 

  

	 	(d)	The RECIPIENT submits a revised copy of the Approved Budget including a narrative justification of the changes prior to incurring costs in the new category. 

All other budget changes or transfers require the INSTITUTE’s express prior written approval. Transfer of funds between categories in the Project’s
Approved Budget may be allowed if requests are in writing, fit within the Scope of Work and the total Approved Budget, are beneficial to the achievement of the objectives of the Project, and appear to be an efficient, effective use of the
INSTITUTE’s funds. 
 Section 3.06 Withholding Payment. The INSTITUTE may withhold Grant award proceeds from the RECIPIENT if required
Financial Status Reports (Form 269a) are not on file for previous quarters or for the final period, if material program requirements are not met and remain uncured after a reasonable time period to cure, if the RECIPIENT is in breach of any material
term of this Contract, or in accordance with provisions of this Contract as well as applicable state or federal laws, regulations or administrative rules, and the breach remains uncured after a reasonable time period to cure. The INSTITUTE shall
have the right to withhold all or part of any future payments to the RECIPIENT to offset any prior advance payments made to the RECIPIENT for ineligible expenditures that have not been refunded to the INSTITUTE by the RECIPIENT 

Section 3.07 Grant Funds as Supplement to Budget. The RECIPIENT shall use the Grant proceeds awarded pursuant to this Contract to supplement its
overall budget. These funds will in no event supplant existing funds currently available to the RECIPIENT that have been previously budgeted and set aside for the Project. The RECIPIENT will not bill the INSTITUTE for any costs under this Contract
that also have been billed or should have been billed to any other funding source. 

  
 ***Confidential
Treatment Requested 
  
 8 

 Section 3.08 Buy Texas. The RECIPIENT shall apply good faith efforts to purchase goods and services
from suppliers in Texas to the extent reasonably possible, to achieve a goal of more than 50 percent of such purchases from suppliers in Texas. 

Section 3.09 Historically Underutilized Businesses. The RECIPIENT shall use reasonable efforts to purchase materials, supplies or services from a
Historically Underutilized Business (HUB). The Texas Procurement and Support Services website will assist in finding HUB vendors (http://www.window.state.tx.us/procurement.) The RECIPIENT shall complete a HUB report with each annual report submitted
to the INSTITUTE in accordance with Attachment E. 
 Section 3.10 Limitation on Use of Grant Award Proceeds to Pay Indirect Costs. The RECIPIENT
shall not spend more than five percent of the Grant award proceeds for Indirect Costs. 
 Section 3.11 Carry Forward of Unspent Funds and No Cost
Extension. RECIPIENT may request to carry forward unspent funds into the budget for the next year. Carryover of unspent funds must be specifically approved by the INSTITUTE. The INSTITUTE may approve a no cost extension for the Contract for a
period not to exceed six (6) months after the Termination Date if additional time beyond the Termination date is required to ensure adequate completion of the approved project. The Contract must be in good fiscal and programmatic standing. All
terms and conditions of the Contract shall continue during any extension period and if such extension is approved, notwithstanding Section 2.03, all references to the “Termination Date” shall be deemed to mean the date of expiration
of such extension period. 
 Article IV 

AUDITS AND INSPECTIONS 

Section 4.01 Record Keeping. The RECIPIENT, each Collaborator and each Contractor whose costs are funded in all or in part by the Grant shall
maintain or cause to be maintained books, records, documents and other evidence (electronic or otherwise) pertaining in any way to its performance under and compliance with the terms and conditions of this Contract
(“Records”). The RECIPIENT, each Collaborator and each Contractor shall use, or shall cause the entity which is maintaining such Records to use generally accepted accounting principles in the maintenance of such Records, and
shall retain or require to be retained all of such Records for a period of four (4) years from the Termination Date of the Contract. 

Section 4.02 Audits. Upon request and with reasonable notice, the RECIPIENT, each Collaborator and each Contractor whose costs are charged to the
Project shall allow, or shall cause the entity which is maintaining such items to allow, the INSTITUTE, or auditors working on behalf of the INSTITUTE, including the State Auditor and/or the Comptroller of Public Accounts for the State of Texas, to
review, inspect, audit, copy or abstract all of its Records during regular working hours. Acceptance of funds directly under the Contract or indirectly through a subcontract under the Contract constitutes acceptance of the authority of the
INSTITUTE, or auditors working on behalf of the INSTITUTE, including the State Auditor and/or the Comptroller of Public Accounts, to conduct an audit or investigation in connection with those funds for a period of four (4) years from the
Termination Date of the Contract. 

  
 9 

 Notwithstanding the foregoing, any RECIPIENT expending $[...***...] or more in federal or state awards during its
fiscal year shall obtain either an annual single audit or a program specific audit. A RECIPIENT expending funds from only one federal program (as listed in the Catalog of Federal Domestic Assistance (CFDA) or one state program may elect to obtain a
program specific audit in accordance with Office of Management and Budget (OMB) Circular A-133 or with the State of Texas Uniform Grant Management Standards (UGMS). A single audit is required if funds from more than one federal or state program are
spent by the RECIPIENT. The audited time period is the RECIPIENT’s fiscal year, not the INSTITUTE funding period. 
 Section 4.03
Inspections. In addition to the audit rights specified in Section 4.02 “Audits”, the INSTITUTE shall have the right to conduct periodic onsite inspections within normal working hours and on a day and a time mutually agreed to by
the parties, to evaluate the Institute-Funded Activity. The RECIPIENT shall fully participate and cooperate in any such evaluation efforts. 

Section 4.04 On-going Obligation to Submit Requested Information. The RECIPIENT shall, submit other information related to the Grant to the
INSTITUTE as may be reasonably requested from time-to-time by the INSTITUTE, by the Legislature or by any other funding or regulatory bodies covering the RECIPIENT’s activities under this Contract. 

Section 4.05 Duty to Resolve Deficiencies. If an audit and/or inspection under this Article IV finds there are deficiencies that should be
remedied, then the RECIPIENT shall resolve and/or cure such deficiencies within a reasonable time frame specified by the INSTITUTE. Failure to do so shall constitute an Event of Default pursuant to Section 8.03 “Event of Default.”
Upon the RECIPIENT’S request, the parties agree to negotiate in good faith, specific extensions so that the RECIPIENT can cure such deficiencies. 

Section 4.06 Repayment of Grant Proceeds for Improper Use. In no event shall RECIPIENT retain Grant funds that have not been used by the RECIPIENT
for purposes for which the Grant was intended or in violation of the terms of this Contract. The RECIPIENT shall repay any portion of Grant proceeds used by the RECIPIENT for purposes for which the Grant was not intended, as determined by the final
results of an audit conducted pursuant to the provisions of this Contract. Unless otherwise expressly provided for in writing and appended to this Contract, the repayment shall be made to the INSTITUTE no later than [...***...] upon a written
request by the INSTITUTE specifying the amount to be repaid and detailing the basis upon which such request is being made and the amount shall include interest calculated at an amount not to exceed five percent (5%) annually. The RECIPIENT may
request that the INSTITUTE waive the interest, subject in all cases to the INSTITUTE’S sole discretion. 
 Section 4.07 Repayment of Grant
Proceeds for Relocation Outside of Texas. The RECIPIENT shall repay the INSTITUTE all Grant proceeds disbursed to RECIPIENT in the event that RECIPIENT relocates its principal place of business outside of the State during the Contract term or
within 3 years after the final payment of the Grant funds is made by the INSTITUTE. 

  
 ***Confidential
Treatment Requested 
  
 10 

 Article V 

ASSURANCES AND CERTIFICATIONS 
 Adoption
of Attachment C. The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment C in their entirety, incorporate them as if fully set forth herein, and agree to perform and be bound by all such terms. 

Article VI 
 INTELLECTUAL
PROPERTY AND REVENUE SHARING 
 Adoption of Attachment D. The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment D in their
entirety, incorporate them as if fully set forth herein, and agree to perform and be bound by all such terms. 
 Article VII 

REPORTING 
 Adoption of Attachment
E. The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment E in their entirety, incorporate them as if fully set forth herein, and agree to perform and be bound by all such terms. 

Article VIII 
 EARLY
TERMINATION AND EVENT OF DEFAULT 
 Section 8.01 Early Termination of Contract. This Contract may be terminated prior to the Termination
Date specified in Section 2.03 “Contract Term” by: 
  

	 	(a)	Mutual written consent of all parties to this Contract; or 

  

	 	(b)	The INSTITUTE for an Event of Default (defined in Section 8.03) by the RECIPIENT; or 

  

	 	(c)	The INSTITUTE if allocated funds should become legally unavailable during the Contract period and the INSTITUTE is unable to obtain additional funds for such purposes; or 

 

	 	(d)	The RECIPIENT for convenience. 

 Section 8.02 Repayment of Grant Proceeds upon Early Termination.
The INSTITUTE may require the RECIPIENT to repay any unused portion of the disbursed Grant proceeds in the event of early termination under 8.01 (d) above or under Section 8.01(b) above, to the extent such Event of Default resulted from
Grant funds being expended in violation of this Contract. To the extent that the INSTITUTE exercises this option, the INSTITUTE shall provide written notice to the RECIPIENT stating the amount to be repaid, applicable interest calculated not to
exceed five percent (5%) annually, and the schedule for such repayment. The RECIPIENT may request that the INSTITUTE waive the interest, subject in all cases to the INSTITUTE’S sole discretion. In no event shall the RECIPIENT retain Grant
funds that have not been used by the RECIPIENT for purposes for which the Grant was intended. 

  
 11 

 Section 8.03 Event of Default. The following events shall, unless expressly waived in writing by the
INSTITUTE or fully cured by the RECIPIENT pursuant to the provisions herein, constitute an event of default (each, an “Event of Default”): 
  

	 	(a)	The RECIPIENT’s failure, in any material respect, to conduct the Project in accordance with the approved Scope of Work and to demonstrate progress towards achieving the milestones set forth in Section 2.02;

  

	 	(b)	The RECIPIENT’s failure to conduct the Project within the State of Texas to the extent required under this Contract unless as otherwise specified in the application, Scope of Work or Approved Budget;

  

	 	(c)	The RECIPIENT’s failure to fully comply, in any material respect, with any provision, term, condition, covenant, representation, certification, or warranty contained in this Contract or any other document
incorporated herein by reference; 

  

	 	(d)	The RECIPIENT’s failure to comply with any applicable federal or state law, administrative rule, regulation or policy with regard to the conduct of the Project; 

 

	 	(e)	The RECIPIENT’s material misrepresentation or false covenant, representation, certification, or warranty made by the RECIPIENT herein, in the Grant application, or in any other document furnished by the RECIPIENT
pursuant to this Contract that was false or misleading at the time that it was made; or 

  

	 	(f)	The RECIPIENT ceases its business operations, has a receiver appointed for all or substantially all of its assets, makes a general assignment for the benefit of creditors, is declared insolvent by a court of competent
jurisdiction or becomes the subject, as a debtor, of a proceeding under the federal bankruptcy code, which such proceedings are not dismissed within ninety (90) days after filing. 

Section 8.04 Notice Required. If the RECIPIENT intends to terminate pursuant to Section 8.01(d) “Early Termination of Contract”, it
shall provide written notice to the INSTITUTE pursuant to the notice provisions of Section 9.21 “Notices” no later than thirty (30) days prior to the intended date of termination. 

If the INSTITUTE intends to terminate for an Event of Default under Section 8.01(b) by the RECIPIENT, as described in Section 8.03 “Event of
Default”, the INSTITUTE shall provide written notice to the RECIPIENT pursuant to Section 9.21 “Notices” and shall include a reasonable description of the Event of Default and, if applicable, the steps necessary to cure such
Event of Default. Upon receiving notice from the INSTITUTE, the RECIPIENT shall have thirty (30) days beginning on the day following the receipt of notice to cure the Event of Default. Upon request, the INSTITUTE may provide an extension of
time to cure the Event of Default(s) beyond the thirty (30) day period specified herein so long as the RECIPIENT is using reasonable efforts to cure and is making reasonable progress in curing such Event(s) of Default. The extension shall be in
writing and appended to the Contract. If the RECIPIENT is unable or fails to timely cure an Event of Default, unless expressly waived in writing by the INSTITUTE, this Contract shall immediately terminate as of the close of business on the final day
of the allotted cure period without any further notice or action by the INSTITUTE required. In addition, and notwithstanding the foregoing, the INSTITUTE and the RECIPIENT agree that certain events that cannot be cured shall, unless
expressly waived in writing by the INSTITUTE, constitute a final Event of Default under this Contract and this Contract shall terminate immediately upon the INSTITUTE giving the RECIPIENT written “Notice of Event of Default and FINAL
TERMINATION.” 

  
 12 

 In the event that the INSTITUTE terminates the Contract under Section 8.01(c) above because allocated funds
become legally unavailable during the Contract period, the INSTITUTE shall immediately provide written notification to the RECIPIENT of such fact pursuant to Section 9.21 “Notices.” The Contract is terminated upon the RECIPIENT’s
receipt of that notification, subject to Section 9.09 “Survival of Terms.” 
 Section 8.05 Duty to Report Event of Default. The
RECIPIENT shall notify the INSTITUTE in writing pursuant to Section 9.21 “Notices”, promptly and in no event more than (30) days after it obtains knowledge of the occurrence of any Event of Default. The RECIPIENT shall include a
statement setting forth reasonable details of each Event of Default and the action which the RECIPIENT proposes to take with respect thereto. 

Section 8.06 Obligations/Liabilities Affected by Early Termination. The RECIPIENT shall not incur new obligations that otherwise would have been
paid for using Grant funds after the receipt of notice as provided by Section 8.04 “Notice Required”, unless expressly permitted by the INSTITUTE in writing, and shall cancel as many outstanding obligations as possible. The INSTITUTE
shall not owe any fee, penalty or other amount for exercising its right to terminate the Contract in accordance with Section 8.01. In no event shall the INSTITUTE be liable for any services performed, or costs or expenses incurred, after the
Termination Date of the Contract. Early termination by either party shall not nullify obligations already incurred, including the RECIPIENT’s revenue sharing obligations as set forth in Attachment D, or the performance or failure to perform
obligations prior to the Termination Date. 
 Section 8.07 Interim Remedies. Upon receipt by the RECIPIENT of a notice of Event of Default, and
at any time thereafter until such Event of Default is cured to the satisfaction of the INSTITUTE or this Contract is terminated, the INSTITUTE may enforce any or all of the following remedies (such rights and remedies being in addition to and not in
lieu of any rights or remedies set forth herein): 
  

	 	(a)	The INSTITUTE may refrain from disbursing any amount of the Grant funds not previously disbursed; provided, however, the INSTITUTE may make such a disbursement after the occurrence of an Event of Default without thereby
waiving its rights and remedies hereunder; 

  

	 	(b)	The INSTITUTE may enforce any additional remedies it has in law or equity. 

 The rights and remedies herein
specified are cumulative and not exclusive of any rights or remedies that the INSTITUTE would otherwise possess. 
 Article IX 

MISCELLANEOUS 
 Section 9.01
Uniform Grant Management Standards. Unless otherwise provided herein, the RECIPIENT agrees that the Uniform Grant Management Standards (UGMS), developed by the Governor’s Budget and Planning Office as directed under the Uniform Grant
Management Act of 1981, TEX. GOVT. CODE, Ch. 783, apply as additional terms and conditions of this Contract and that the standards are adopted by reference in their entirety. If there is a conflict between the provisions of this Contract and UGMS,
the provisions of this Contract will prevail unless expressly stated otherwise. 

  
 13 

 Section 9.02 Management and Disposition of Equipment. During the term of this Contract, the RECIPIENT
may use Grant funds to purchase Equipment to be used for the authorized purpose of the Project, subject to the conditions set forth below. Unless otherwise provided herein, title to Equipment shall vest in the RECIPIENT upon termination of the
Contract. 
  

	 	(a)	The INSTITUTE must authorize the acquisition in advance and in writing but an acquisition is deemed authorized if included in the Approved Budget for the Project; 

 

	 	(b)	Equipment purchased with Grant funds must stay within the State of Texas; 

  

	 	(c)	Equipment purchased with Grant funds must be materially deployed to the uses and purposes related to the Project; 

  

	 	(d)	In the event the RECIPIENT is indemnified, reimbursed or otherwise compensated for any loss of, destruction of, or damage to the Equipment purchased using Grant funds, it shall use the proceeds to repair or replace said
Equipment; 

  

	 	(e)	Equipment may be exchanged (trade-in) or sold without the prior written approval of the INSTITUTE if the proceeds thereof shall be applied to the acquisition cost of replacement Equipment; 

 

	 	(f)	The RECIPIENT may use its own property management standards and procedures provided that it observes the terms of UGMS, A-102, in all material respects; 

 

	 	(g)	The title or ownership of the Equipment shall not be encumbered for purposes other than the Project nor or transferred other than to a permitted assignee of this Contract without the prior written approval of the
INSTITUTE; 

  

	 	(h)	If the original or replacement Equipment is no longer needed for the originally authorized purpose or for other activities supported by the INSTITUTE, the RECIPIENT shall request disposition instructions from the
INSTITUTE and, upon receipt, shall fully comply therewith; and 

  

	 	(i)	If this Contract is terminated early pursuant to Section 8.01(b),(d), (e) or (f) above, the INSTITUTE shall determine the final disposition of Equipment purchased with Grant award money.

 Section 9.03 Supplies and Other Expendable Property. The RECIPIENT shall classify as materials, supplies and other expendable
property the allowable unit acquisition cost of such property under $5,000 necessary to carry out the Project. Title to supplies and other expendable property shall vest in the RECIPIENT upon acquisition. 

Section 9.04 Acknowledgement of Grant Funding and Publicity. The parties agree to the following terms and conditions regarding acknowledging Grant
funding and publicity: 
  

	 	(a)	The parties agree to fully cooperate and coordinate with each other in connection with all press releases and publications regarding the award of the Grant, the execution of the Contract and the Institute-Funded
Activities. 

  
 14 

	 	(b)	The RECIPIENT shall notify the INSTITUTE’s Information Specialist or similar personnel at least three business days prior to any press releases, advertising, publicity, use of CPRIT logo, or other promotional
activities that pertain to the Project or any Institute-Funded Activity. In the event that the INSTITUTE wishes to participate in a joint press release, the RECIPIENT shall coordinate and cooperate with the INSTITUTE’s Information Specialist or
similar personnel to develop a mutually agreeable joint press release. 

  

	 	(c)	Consistent with the goal of encouraging development of scientific breakthroughs and dissemination of knowledge, publication or presentation of scholarly materials is expected and encouraged. The RECIPIENT may publish in
scholarly journals or other peer-reviewed journals (including graduate theses and dissertations) and may make presentations at scientific meetings without prior notice to or consent of the INSTITUTE, except as may otherwise be set forth in this
Contract. The RECIPIENT shall promptly notify the INSTITUTE when any scholarly presentations or publications have been accepted for public disclosure and shall provide the INSTITUTE with final copies of all such accepted presentations and
publications. The RECIPIENT shall acknowledge receipt of the INSTITUTE funding in all publications, presentations, press releases and other materials regarding the work associated with the Institute-Funded Activities. The RECIPIENT shall promptly
submit an electronic version of all published manuscripts to PubMed Central in accordance with Section 9.05 “Public Access to Research Results.” 

  

	 	(d)	When grant funds are used to prepare print or visual materials for educational or promotional purposes for the general public (e.g., patients), and excluding presentations and publications discussed above in subsection
(c), the RECIPIENT shall provide a copy of such materials to the INSTITUTE at least ten (10) days prior to printing. The RECIPIENT shall also acknowledge receipt of the INSTITUTE funding on all such materials including, but not limited to,
brochures, pamphlets, booklets, training fliers, project websites, videos and DVDs, manuals and reports, as well as on the labels and cases for audiovisual or videotape/DVD presentations. 

Section 9.05 Public Access to Results of Institute-Funded Activities. The RECIPIENT shall submit an electronic version of its final peer-reviewed
journal manuscripts that arise from Grant funds to the digital archive National Library of Medicine’s PubMed Central upon acceptance for publication. These papers must be accessible to the public on PubMed no later than 12 months after
publication. This policy is subject to the terms of Attachment D and does not supplant applicable copyright law. For clarity, this policy is not intended to require the RECIPIENT to make a disclosure at a time or in any manner that would cause the
RECIPIENT to abandon, waive or disclaim any intellectual property rights that it is obligated to protect pursuant to the terms of Attachment D. 

Section 9.06 Work to be Conducted in State. The RECIPIENT agrees that it will use reasonable efforts to direct that any new or expanded
preclinical testing, clinical trials, commercialization or manufacturing that is part of or relating to any Institute-Funded Activities take place in the State of Texas, including the establishment of facilities to meet this purpose. If the
RECIPIENT decides not to conduct such work in the State of Texas, the RECIPIENT shall provide a prior written explanation to the INSTITUTE detailing the RECIPIENT’s reasons for conducting the work outside of the State of Texas and the
RECIPIENT’s efforts made to conduct the work in the State of Texas 
 Section 9.07 Duty to Notify. During the term of this Contract and for
a period of [...***...] thereafter, the RECIPIENT is under a continuing obligation to notify the INSTITUTE’s executive director at the same time it is required to notify any Federal or State entity of any unexpected adverse event

  
 ***Confidential
Treatment Requested 
  
 15 

 
or condition that materially impacts the performance or general public perception of the conduct or results of the Project and the Institute-Funded Activities, including any impact to the Scope
of Work included in the Contract and events or results that have a serious adverse impact on human health, safety or welfare. By way of example only, if clinical testing of the results of the Institute-Funded Activities reveal an unexpected risk of
developing serious health conditions or death, then the RECIPIENT shall, at the same time it notifies any Federal or State entity, promptly so notify the INSTITUTE’s executive director even if such results are not available until after the term
of this Contract. Notice required under this section shall be made as promptly as reasonably possible and shall follow the procedures set forth in Section 9.21 “Notices.” 

Section 9.08 Severability. If any provision of this Contract is construed to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or enforceability shall not affect any other provisions hereof. The invalid, illegal or unenforceable provision shall be deemed stricken and deleted to the same extent and effect as if never incorporated herein. All other provisions shall
continue as provided in this Contract. 
 Section 9.09 Survival of Terms. Termination or expiration of this Contract for any reason will not
release either party from any liabilities or obligations set forth in this Contract that: (1) the Parties have expressly agreed shall survive any such termination or expiration; or (2) remain to be performed or by their nature would be
intended to be applicable following any such termination or expiration. Such surviving terms include, but are not limited to, Sections 2.13, 4.01, 4.02, 4.05, 4.06, 8.02, 8.06, 9.04, 9.05, 9.06, 9.07, 9.09, 9.14, 9.15, 9.16, 9.17, 9.18, and
Attachment D. 
 Section 9.10 Binding Effect and Assignment or Modification. This Contract and all terms, provisions and obligations set forth
herein shall be binding upon and shall inure to the benefit of the parties and their successors and permitted assigns, including all other state agencies and any other agencies, departments, divisions, governmental entities, public corporations or
other entities which shall be successors to either of the parties or which shall succeed to or become obligated to perform or become bound by any of the covenants, agreements or obligations hereunder of either of the parties hereto. Upon a permitted
assignment of this Contract by RECIPIENT, all references to “the RECIPIENT” herein shall be deemed to refer to such permitted assignee. 

Section 9.11 No Waiver of Contract Terms. Neither the failure by the RECIPIENT or the INSTITUTE, in any one or more instances, to insist upon the
complete and total observance or performance of any term or provision hereof, nor the failure of the RECIPIENT or the INSTITUTE to exercise any right, privilege or remedy conferred hereunder or afforded by law, shall be construed as waiving any
breach of such term or provision or the right to exercise such right, privilege or remedy thereafter. In addition, no delay on the part of either the RECIPIENT or the INSTITUTE, in exercising any right or remedy hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any right or remedy preclude other or further exercise thereof or the exercise of any other right or remedy. 

Section 9.12 No Waiver of Sovereign Immunity. No provision of this Contract is in any way intended to constitute a waiver by the INSTITUTE, the
RECIPIENT (if applicable), or the State of Texas of any immunities from suit or from liability that the INSTITUTE, the RECIPIENT, or the State of Texas may have by operation of law. 

  
 16 

 Section 9.13 Force Majeure. Neither the INSTITUTE nor the RECIPIENT will be liable for any failure or
delay in performing its obligations under the Contract if such failure or delay is due to any cause beyond the reasonable control of such party, including, but not limited to, unusually severe weather, strikes, natural disasters, fire, civil
disturbance, epidemic, war, court order or acts of God. The existence of such causes of delay or failure will extend the period of performance in the exercise of reasonable diligence until after the causes of delay or failure have been removed. Each
party must inform the other in accordance with Section 9.21 “Notices” within five (5) business days, or as soon as it is practical, of the existence of a force majeure event or otherwise waive this right as a defense. 

Section 9.14 Disclaimer of Damages. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, PUNITIVE, EXEMPLARY,
INCIDENTAL OR CONSEQUENTIAL DAMAGES. THIS LIMITATION WILL APPLY REGARDLESS OF WHETHER OR NOT THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

Section 9.15 Indemnification and Hold Harmless. Except as provided herein, the RECIPIENT agrees to fully indemnify and hold the INSTITUTE and the
State of Texas harmless from and against any and all claims, demands, costs, expenses, liabilities, causes of action and damages of every kind and character (including reasonable attorneys fees) which may be asserted by any third party in any way
related or incident to, arising out of, or in connection with (1) the RECIPIENT’s negligent, intentional or wrongful performance or failure to perform under this Contract, (2) the RECIPIENT’s receipt or use of Grant funds, or
(3) any negligent, intentional or wrongful act or omission committed by the RECIPIENT as part of an Institute-Funded Activity or during the Project. In addition, the RECIPIENT agrees to fully indemnify and hold the INSTITUTE and the State of
Texas harmless from and against any and all costs and expenses of every kind and character (including reasonable attorneys fees, costs of court and expert fees) that are incurred by the INSTITUTE or the State of Texas arising out of or related to a
third party claim of the type specified in the preceding sentence. Notwithstanding the preceding, such indemnification shall not apply in the event of the sole or gross negligence of the INSTITUTE. If the RECIPIENT is a State of Texas agency or
institution of higher education, then this Section 9.15 is subject to the extent authorized by the Texas Constitution and the laws of the State of Texas. 

The RECIPIENT acknowledges and agrees that this indemnification shall apply to, but is not limited to, employment matters, taxes, personal injury, and
negligence. 
 It is understood and agreed that it is not the intent of the parties to expand or increase the liability of the State of Texas under this
Article. This provision is intended to prevent the RECIPIENT, the INSTITUTE and the State of Texas from attempting or appearing to assume liability it does not have the statutory or legal power to assume. 

Section 9.16 Alternative Dispute Resolution. If applicable, the dispute resolution process provided for in TEX. GOVT. CODE, Ch. 2260 shall be
used, as further described herein, to resolve any claim for breach of contract made against the INSTITUTE (excluding any uncured Event of Default). The submission, processing and resolution of a party’s claim are governed by the published rules
adopted by the Attorney General pursuant to TEX. GOVT. CODE, Ch. 2260, as currently effective, hereafter enacted or subsequently amended. 

Section 9.17 Applicable Law and Venue. This Contract shall be construed and all disputes shall be considered in accordance with the laws of the
State of Texas, without regard to its principles governing the conflict of laws. Provided that the RECIPIENT first complies with procedures set forth in Section 9.16 “Alternative Dispute Resolution,” exclusive venue and jurisdiction
for the resolution of claims arising from or related to this Contract shall be in the federal and state courts in Travis County, Texas. 

  
 17 

 Section 9.18 Attorneys’ Fees. In the event of any litigation, appeal or other legal action to
enforce any provision of the Contract, the RECIPIENT shall pay all expenses of such action, including attorneys’ fees and costs, if the INSTITUTE is the prevailing party. If the RECIPIENT is a State of Texas agency or institution of higher
education, then this Section 9.18 is subject to the extent authorized by the Texas Constitution and the laws of the State of Texas. 

Section 9.19 Counterparts. This Contract may be executed in any number of counterparts, each of which when so executed and delivered shall be an
original, but such counterparts shall together constitute one and the same instrument. 
 Section 9.20 Construction of Terms. The headings used
in this Contract are inserted only as a matter of convenience and for reference and shall not affect the construction or interpretation of this Contract. Where context so indicates, a word in the singular form shall include the plural, a word in the
masculine form the feminine, and vice-versa. The word “including” and similar constructions (such as “includes”, “included”, “for example”, “such as”, and “e.g.”) shall mean
“including, without limitation” throughout this Contract. The words “and” and “or” are not intended to convey exclusivity or nonexclusivity except where expressly indicated or where the context so indicates in order to
give effect to the intent of the parties. 
 Section 9.21 Notices. All notices, requests, demands and other communications will be in writing
and will be deemed given on the date received as demonstrated by (i) a courier’s receipt or registered or certified mail return receipt signed by the party to whom such notice was sent, provided that such notice was sent to the address
provided in the signature block of this Contract, or (ii) a fax confirmation page showing that such fax was successfully transmitted to the fax number provided in the signature block of this Contract. Notices shall be sent to the parties at the
addresses or fax numbers specified herein or as may be updated from time to time by the applicable party in a writing delivered to the other party pursuant to the terms of this Section. 

  
 18 

 IN WITNESS THEREOF, THE PARTIES HAVE SIGNED AND EXECUTED IN DUPLICATE COUNTERPARTS ON THE DATES INDICATED.

  

									
	RECIPIENT	 		 	INSTITUTE
					
	By	 	 /s/ Thomas J. Farrell, CEO
	 		 	By	 	 /s/ William Gimson

									
	(Signature of Person Authorized to Sign Contracts)	 		 		 	
	Name:	 	Thomas J. Farrell, CEO	 		 	Name:	 	William “Bill” Gimson, Executive Director
	Date:	 	7/27/11	 		 	Date:	 	July 27, 2011

  

			
	RECIPIENT Mailing Address:	  	INSTITUTE Mailing Address:
	BELLICUM PHARMACEUTICALS, INC.	  	 Cancer Prevention and Research Institute of TX

Grant Compliance

	6400 Fannin St., Suite 2300, Houston, TX 77030	  	 P.O. Box 12097
 Austin, TX 78711

		
		  	INSTITUTE Physical Address:
	Physical Address: (If different from above)	  	 211 E. 7th Street, Suite 300

Austin, TX 78701

		
		  	Phone: (512) 463-3190
		
	Phone: (713) 341-6472	  	Fax: (512) 475-2563
	Fax: (713) 335-1446	  	

 

 
  

 ATTACHMENT A 

Project Description Summary 
 The project encompasses
preparation for and execution of a Phase 2 clinical trial, protocol number BP- HM-001, currently entitled “[...***...]”. The Principal Investigator will be Dr. Richard Champlin, Chairman, Department of Stem Cell Transplantation and
Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, which will also be the primary clinical trial site. Up to [...***...] additional sites will be recruited to participate in the trial, including other sites in Texas. 

Preparation activities include the following: 
  

	 	•	 	[...***...] 

 Activities during the clinical trial include the following: 

 

	 	•	 	[...***...] 

 Project Goals and Timelines 

  
 ***Confidential
Treatment Requested 
 Page A1 

 The primary project goals are to [...***...]. The timeline is summarized by quarter as follows: 

 

													
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 	 	[...***...]	 	[...***...]	 	[...***...]
	 	 	 	 
	 	 	 [...***...]

[...***...]
 [...***...]

 
	 	 [...***...]

 
	 	 [...***...]

 

	 	 	 	 
	 	 	 [...***...]

[...***...]
 [...***...]

[...***...]
  
	 	 [...***...]

[...***...]
 [...***...]

[...***...]
  
	 	 [...***...]

[...***...]
 [...***...]

[...***...]
  

 The primary milestone to be achieved in Year 1, which will be the milestone for Year 2 funding, is [...***...] in the clinical
trial. This milestone depends on the achievement of earlier milestones, including [...***...]. This primary milestone is expected to occur approximately [...***...]. 

The primary milestone to be achieved in Year 2, which will be the milestone for Year 3 funding, is [...***...]. Because [...***...]. 

The primary milestone to be achieved in Year 3, and for the project as a whole, is [...***...] 

  
 ***Confidential
Treatment Requested 
 Page A2 

 

 
  

 Application ID: RP110508 

Principal Investigator/Program Director: K. Slavin 

ATTACHMENT B 
 DETAILED
BUDGET FORM 
  

													
	BUDGET CATEGORY	 	Year 1	 	Year 2	 	Year 3	 	Year 4	 	Year 5	 	TOTAL
	
a. PERSONNEL
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	
b. FRINGE BENEFITS
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 c.
TRAVEL
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 d.
EQUIPMENT
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 e.
SUPPLIES
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 f.
CONTRACTUAL
	 	 	 	 	 	 	 	 	 	 	 	 
	 Process
Development
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	
Clinical Lot Manufacturing
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 Data
Management
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 Research-Related Subject C
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 g.
OTHER
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 h.
Total Direct Charges
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 i.
Indirect Charges
	 	[...***...]	 	[...***...]	 	[...***...]	 	 	 	 	 	[...***...]
	 Grand
TOTAL
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

			
	Texas/Federal Vendor ID#:	  	12014502004000
	Fiscal contact:	  	Thomas Farrell
	Address:	  	6400 Fannin St., Suite 2300
	Address 2:	  	Houston, TX 77030
	Phone:	  	(713) 341-6472
	Fax:	  	(713) 335-1446
	Email:	  	tfarrell@bellicum.com

 For questions regarding this form, please contact Alfonso Royal at (512) 305-8488 or oroyal@cprit.state.tx.us. 

  
 ***Confidential
Treatment Requested 
 Page B1 

 

 
  

 ATTACHMENT C 

ASSURANCES AND CERTIFICATIONS 
 This
Attachment C is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (“Contract”) by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”
or the “INSTITUTE”) and the RECIPIENT. A capitalized term used in this Attachment shall have the meaning given to term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a
conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. Notwithstanding any other provision of this Attachment C, each reference to “compliance” in the foregoing certifications
and assurances shall mean “compliance in all material respects” and the RECIPENT shall be deemed to be in compliance with a law, regulation or policy identified in a particular certification or assurance specified in this Attachment C if
the RECIPIENT is in compliance in all materials respects with such law, regulation or policy, as applicable. 
 By signing this Contract, RECIPIENT
certifies compliance with the following assurances and certifications required by the INSTITUTE (listed below). RECIPIENT further acknowledges that its obligations pursuant to the following assurances and certifications are ongoing. 

Section C1.01 Demonstration of Matching Funds. Pursuant to TEX. HEALTH & SAFETY CODE § 102.255(d) and T.A.C. § 703.11, RECIPIENT has
an amount of funds equal to one-half of the amount of the Grant to be disbursed each fiscal year of the Contract term dedicated to the same area of cancer research that is the subject of the Grant as demonstrated by the form incorporated herein to
Attachment C. The RECIPIENT shall update the matching funds certification annually for each fiscal year that Grant funds are disbursed. The update must be on or before the anniversary of the Effective Date. 

Section C1.02 Payment of Taxes. RECIPIENT’s payment of franchise taxes is current or, if the RECIPIENT is exempt from payment of franchise taxes,
that it is not subject to the State of Texas franchise tax. If franchise tax payments become delinquent during the Contract term, payments under this Contract may, upon delivery of written notice by the INSTITUTE to the RECIPIENT be withheld until
the RECIPIENT’s delinquent franchise tax is paid in full. The RECIPIENT also acknowledges that it is not otherwise exempt from state sales or occupancy tax as a result of this Contract. 

Section C1.03 Compliance with Confidentiality Guidelines Relating to Personal and Medical Information. RECIPIENT complies with all applicable laws,
rules and regulations relating to personal and medical information. Without in any way limiting the foregoing, RECIPIENT maintains and enforces, to the extent applicable to RECIPIENT, appropriate facility and information technology access rules and
procedures to protect against inappropriate disclosure of patient records and all other documents containing patient personal and medical information deemed confidential by law, which are maintained in connection with the Project and
Institute-Funded Activities, including provisions that comply with the requirements of the INSTITUTE’s rules, 25 T.A.C. Section 703.14. Upon request from the INSTITUTE, RECIPIENT will timely furnish a copy of the RECIPIENT’s facility
and information technology access rules and procedures, as well as any other applicable confidentiality guidelines. 
 If RECIPIENT, including any
Collaborators or Contractors, works directly with patients or otherwise has access to or maintains patient personal and medical information, RECIPIENT specifically addresses Health Insurance Portability and Accountability Act of 1996 regulations
concerning confidentiality of personal and medical information. Any disclosure of patient confidential information in any way related to the Project (including information that may be required by reports and inspections) must be in accordance with
all applicable laws. 

  
 Page C1 

 

 
  

 Section C1.04 Conduct of Research or Service Provided. RECIPIENT understands that the Project must be
conducted with full consideration for the ethical and medical implications of the research performed or services delivered and comply with all applicable federal and state laws regarding the conduct of the research or service. 

Section C1.05 Regulatory Certificates, Licenses and Permits. All of the RECIPIENT’s personnel, facilities and equipment involved or to be involved
in the Project are certified, licensed, permitted, registered or approved by the appropriate regulating agency, where applicable. Any revocation, surrender, expiration, non-renewal, inactivation or suspension of any such certification, license,
permit, registration or approval shall constitute grounds for Contract termination if the same is not remedied (or alternative personnel, facilities and/or equipment identified, as applicable, for use in the Project) within the applicable cure
period specified in Section 8.04. 
 Section C1.06 Assurances and Certifications in Accordance with the NIH Grants Policy
Statement: 
 (a) Civil Rights. Compliance with Title VI of the Civil Rights Act of 1964. 

(b) Handicapped Individuals. Compliance with Section 504 of the Rehabilitation Act of 1973 as amended. 

(c) Sex Discrimination. Compliance with Section 901 of Title IX of the Education Amendments of 1972 as amended. 

(d) Age Discrimination. Compliance with the Age Discrimination Act of 1975, as amended. 

(e) Patents, Licenses and Inventions. Compliance with the Standard Patent Rights clauses as specified in 37 CFR, Part 401 or 35 U.S.C.
203, if appropriate and applicable, in a manner that adequately protects the INSTITUTE’S rights in the Project Results. 
 (f) Human
Subjects. Compliance with the requirements of federal policy concerning the safeguarding of the rights and welfare of human subjects who are involved in activities supported by federal funds. Before any funding may be utilized for any portion of
the Project involving human subjects, RECIPIENT must receive approval from RECIPIENT’s Institutional Review Board (IRB). Upon request, a copy of RECIPIENT’s IRB approval must be provided to the INSTITUTE. 

(g) Human Biological/Anatomical Material. Compliance with the recommendations of the NIH Office of Human Subject Research Medical
Administrative Series (MAS) #MO1-2 entitled “Procurement and Use of Human Biological Materials for Research,” and any other applicable federal or state requirements pertaining to the procurement and use of human biological material for
research. 
 (h) Use of Animals. Compliance with applicable portions of the Animal Welfare Act (PL 89-544 as amended) and appropriate
Public Health Service Policy on Humane Care and Use of Laboratory Animals regulations. Before any funding may be utilized for any portion of the Project involving animal subjects, RECIPIENT must receive approval from RECIPIENT’s Institutional
Animal Care and Use Committee (IACUC). Upon request, a copy of RECIPIENT’s IACUC approval must be provided to the INSTITUTE. 

  
 Page C2 

 

 
  

 (i) Debarment and Suspension. RECIPIENT certifies that neither it nor the Principal
Investigator/Project Director or any other Recipient Personnel or personnel of any Collaborator or Contractor assigned to work on the Project are debarred, suspended, proposed for debarment, declared ineligible or otherwise excluded from
participation in the Project by any federal or state department or agency. 
 (j) Non-Delinquency on Federal or State Debt. RECIPIENT
certifies that neither it, nor, to its knowledge, any person to be paid from funds under this Contract, is delinquent in repaying any Federal debt as defined by OMB Circular A-129 or any debt to the State of Texas. 

(k) Eligibility to Receive Payments on State Contracts. RECIPIENT certifies that it and, to its knowledge, the Principal
Investigator/Project Director are not ineligible to receive the Grant award under this Contract pursuant to Tex. Fam. Code Ann. Section 231.006 and acknowledges that this Contract may be terminated and payment may be withheld if this
certification is inaccurate. 
 (l) Drug-Free Workplace. Compliance with the Drug-Free Workplace Act of 1988 (45 CFR 82). 

(m) Misconduct in Science. Compliance with 42 CFR Part 50, Subpart A, and Final Rule as published at 54 CFR 32446, August 8,
1989. 
 (n) Objectivity of Research/Conflict of Interest. Compliance with the NIH requirement to maintain a written standard of
conduct and comply with 42 CFR Part 50, Subpart F, Responsibility of Applicants for Promoting Objectivity in Research. RECIPIENT must notify the INSTITUTE of any conflicting financial interests pertaining to the performance of the Project and assure
that such conflict of interest has been appropriately managed, reduced or eliminated. 
 (o) Trafficking in Persons. Compliance with
the NIH regulations on trafficking in persons as published at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-055.html. 
 (p)
Criminal Misconduct. RECIPIENT shall promptly report to the INSTITUTE issues involving potential civil or criminal fraud related in any way to the Project, the Institute-Funded Activity or this Contract, such as false claims or
misappropriation of federal or state funds. 

  
 Page C3 

	
	

  
 Page C4 

 

 
  

 ATTACHMENT D 

INTELLECTUAL PROPERTY AND REVENUE SHARING 

This Attachment D is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (“Contract”) by
and between the Cancer Prevention and Research Institute of Texas (“CPRIT” or the “INSTITUTE”) and the RECIPIENT. A capitalized term used in this Attachment shall have the meaning given the term in the
Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. 

PART 1 
 OWNERSHIP AND
INTELLECTUAL PROPERTY PROTECTION 
 Section D1.01 Ownership of Project Results. RECIPIENT and its Collaborators shall retain ownership of the
Institute-Funded Technology and the Institute-Funded IPR, subject to the terms of the Contract. 
 Section D1.02 Transfer or Assignment of Rights to a
Third Party. RECIPIENT shall notify the INSTITUTE of any proposed transfer or assignment of rights in any Institute-Funded IPR to a third party. RECIPIENT shall ensure that, in any assignment or transfer of Institute-Funded IPR, the transferee
or assignee agrees in writing to (i) recognize that the Institute-Funded IPR is transferred or assigned subject to the licenses, interests and other rights in such Institute-Funded IPR provided to the INSTITUTE in the Contract and any
applicable law or regulation, and (ii) take all actions necessary to protect all such licenses, interests and other rights. 
 Section D1.03
Protection of Institute-Funded IPR. Subject to Section D5.01RECIPIENT shall use commercially reasonable efforts to appropriately protect the Institute-Funded IPR, including without limitation, diligently seeking registration of patents and
copyrights covering the Institute-Funded Technology, as appropriate. If RECIPIENT elects to abandon Institute-Funded IPR (including any partial abandonment of Institute-Funded IPR in specific territories), RECIPIENT shall provide the INSTITUTE with
prior written notice of such election, with sufficient time (but no less than 30 days) for the INSTITUTE to exercise its rights in Section D5.01 in relation to the subject Institute-Funded IPR. 

Section D1.04 Cost of Protection. The INSTITUTE shall not be responsible for, and no Grant funds may be used to pay for, any costs or expenses
associated with RECIPIENT’s efforts to protect the Institute-Funded IPR. 
 Section D1.05 Inventions. 

(a) Disclosures. RECIPIENT shall notify INSTITUTE of each Institute-Funded Invention by delivering a copy of the invention disclosure
form (or similar document) within [...***...] after RECIPIENT receives the form from its Inventor. In the event that the invention disclosure form is revised or updated, RECIPIENT shall provide the INSTITUTE with the revised/updated invention
disclosure form as part of the RECIPIENT’s annual written report. 
 (b) Patent Prosecution and Maintenance. For all
Institute-Funded Inventions for which patent protection is pursued, RECIPIENT shall provide an annual written report to the INSTITUTE regarding the status of pending applications and issued patents . 

Section D1.06 Required Agreements with Recipient Personnel and Contractors. The RECIPIENT shall have, maintain and enforce written policies or
agreements applicable to Recipient Personnel and 

  
 ***Confidential
Treatment Requested 
 Page D1 

 

 
  

 
Contractors with terms sufficient to enable RECIPIENT to fully comply with all terms and conditions of this Contract. RECIPIENT shall promptly report to INSTITUTE any material breach of such
policies or agreements relating to or affecting any of the material provisions of this Contract. 
 Section D1.07 Agreements with Collaborators. All
agreements between RECIPIENT and a Collaborator relating to or affecting joint ownership of any Project Result shall recognize the licenses, interests and other rights provided to the INSTITUTE in the Contract. RECIPIENT shall provide to the
INSTITUTE a copy of each such agreement affecting joint ownership of any Project Result. 
 PART 2 

NON-COMMERCIAL LICENSES 
 Section
D2.01 RECIPIENT License. In granting an Exclusive License to any Project Result, RECIPIENT shall retain the right to Exploit all Project Results (including material embodiments thereof) for education, research and other non-commercial purposes,
and the right to grant the licenses pursuant to Section D2.02 below. 
 Section D2.02 INSTITUTE License. RECIPIENT agrees to grant, and does hereby
grant, to the INSTITUTE a non-exclusive, irrevocable, royalty-free, perpetual, worldwide license under the Institute-Funded IPR to Exploit all Project Results (including material embodiments thereof) for or on behalf of the INSTITUTE and other
governmental entities and agencies of the State of Texas for education, research and other non-commercial purposes only. RECIPIENT shall make the Institute-Funded Technology available by reasonable means to the INSTITUTE in order for the INSTITUTE
to exercise its rights under this Section. The INSTITUTE may not transfer or sublicense the licenses granted under this Section, except to the State of Texas or other Texas agency. 

Section D2.03 No Implied Licenses. No implied licenses are granted under this Agreement including any license to any Intellectual Property Rights owned
or controlled by RECIPIENT outside of the Institute-Funded IPR. Nothing in this Agreement shall be construed to impose an obligation on RECIPIENT to license or otherwise make available any of its Intellectual Property Rights or other resources owned
or controlled by it except as expressly provided in this Agreement with respect any Institute Funded IPR. 
 PART 3 

COMMERCIALIZATION OF PROJECT RESULTS 

Section D3.01 Commercialization Strategy. RECIPIENT shall be under a continuing obligation throughout the term of this Contract to enhance and improve
the commercial development plan submitted with the Application and to provide an annual written report to the INSTITUTE regarding the RECIPIENT’s efforts to commercialize or otherwise bring to practical application Project Results. The
INSTITUTE may, at its option and at any time, provide RECIPIENT with comments regarding the RECIPIENT’s commercial development plan and strategy, in which case RECIPIENT shall consider in good faith and use reasonable efforts to account for and
incorporate the INSTITUTE’s input into such commercial development plan and strategy. 
 Section D3.02 Commercialization Efforts. The RECIPIENT
shall, whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize or otherwise bring to practical application the
Project Results in accordance with the commercial development plan described in Section D3.01. 
 Section D3.03 Licensing of Project Results. Each
License Agreement entered into by the RECIPIENT shall include an acknowledgement by the licensee that (i) such License Agreement is subject to the INSTITUTE’s licenses, interests and other rights under this Contract, and (ii) to the
extent that there is a conflict between the terms of the License Agreement and the terms of this Contract, the terms of this 

  
 Page D2 

 

 
  

 Contract shall prevail. In addition, all License Agreements shall include terms obligating the licensee to
report to the RECIPIENT such information as is required for the RECIPIENT to fully comply with the terms of the Contract, including without limitation the reporting obligations set forth in Attachment E, and to allow RECIPIENT to make the grants
specified in Sections D2.02. The RECIPIENT shall monitor the performance of its licensees and such licensees’ compliance with the terms of the License Agreements and shall take commercially reasonable actions to enforce the terms of all License
Agreements. The RECIPIENT shall promptly report to the INSTITUTE any material breach of a License Agreement relating to or affecting any of the material provisions of this Contract. 

Section D3.04 Cost of Licensing Activities. The INSTITUTE shall not be responsible for, and no Grant funds may be used to pay for, any costs or
expenses associated with the RECIPIENT’s Licensing Activities. 
 Section D3.05 Survival. The licenses, rights and obligations set forth in this
Attachment D shall survive any termination of this Contract, including any termination for convenience by RECIPIENT, except in the event that RECIPIENT pays the Buyout Amount as set forth in Part 4, in which case the licenses, rights and obligations
set forth in this Attachment D shall automatically terminate. 
 Section D3.06 Recipient Opt-Out. RECIPIENT may, after diligently attempting to
comply with the terms of Section D3.02, notify the INSTITUTE in writing that it is electing to cease its efforts, either directly or through a licensee, to commercialize or otherwise bring to practical application any particular Project Results.
Such written notice must identify the applicable Project Results, provide a reasonable explanation of the reasons for RECIPIENT’s election, including any feasibility studies, trial results, regulatory impediments, financial analyses or similar
assessments, and must identify any deadlines in relation to the applicable Project Results that then exist. Upon receipt of such notice, the INSTITUTE shall have the option, but not the obligation, to exercise its rights in Section 5.01 in
relation to the subject Project Results at the INSTITUTE’s expense. The INSTITUTE shall notify the RECIPIENT in writing within thirty (30) days of its receipt of the RECIPIENT’s notice if the INSTITUTE elects to exercise its rights in
relation to the subject Project Results. In the event that the INSTITUTE exercises its option under this section, the RECIPIENT shall fully cooperate with the INSTITUTE’s efforts, in commercializing or otherwise bringing to practical
application the applicable Project Results. 
 PART 4 

REVENUE SHARING 
 Section D4.01
Revenue Sharing; Buyout. 
 (a) RECIPIENT shall pay to INSTITUTE royalties as follows: 

(i) [...***...]% of all Revenues until the aggregate amount of royalties paid to INSTITUTE pursuant to this Section D4.01(a)(i) equals
[...***...]% of Net Grant Award Proceeds; and 
 (ii) [...***...] % of all Revenues thereafter. 

(b) Notwithstanding anything to the contrary in this Section D4.01, upon RECIPIENT’s written notice of the Buyout Notice Trigger Event to
INSTITUTE at any time after the Termination Date (the “Buyout Notice”), RECIPIENT may, in lieu of paying any additional royalties to INSTITUTE pursuant to Section D4.01(a), pay to INSTITUTE the dollar amount set forth in the
following table opposite the applicable period in which such Buyout Notice is delivered (the applicable dollar amount being referred to as the “Buyout Amount”): 

  
 ***Confidential
Treatment Requested 
 Page D3 

 

 
  

			
	 Period in Which Buyout Notice is Delivered
	  	 Buyout Amount

	 On or prior to the fifth anniversary of the Termination Date
	  	[...***...]% of Net Grant Award Proceeds less the aggregate amount of all royalties paid to INSTITUTE pursuant to Section D4.01(a) as of the date of the Buyout Notice.
		
	 After the fifth anniversary of the Termination Date but on or prior to the tenth anniversary of the Termination Date
	  	[...***...]% of Net Grant Award Proceeds less the aggregate amount of all royalties paid to INSTITUTE pursuant to Section D4.01(a) as of the date of the Buyout Notice.
		
	 After the tenth anniversary of the Termination Date
	  	[...***...]% of Net Grant Award Proceeds less the aggregate amount of all royalties paid to INSTITUTE pursuant to Section D4.01(a) as of the date of the Buyout Notice.

 After satisfaction of its obligations under this Section D4.01(b), RECIPIENT shall have no further obligation
under this Section D4.01. 
 (d) “Net Grant Award Proceeds” means the aggregate amount of Grant award proceeds
advanced to RECIPIENT, net of any Grant award proceeds repaid by RECIPIENT to INSTITUTE, including, without limitation, pursuant to Section 4.07 of the Contract. 

Section D4.02 Adjustments. If any funding sources other than the INSTITUTE (but excluding RECIPIENT) contribute funds, directly or indirectly, to the
research yielding any particular Project Result(s) and such funding sources are legally or contractually entitled to receive royalty based compensation with respect to such Project Result(s) (hereinafter a “Participating Funding
Source”), then the royalty percentages in Section D4.01(a) in effect at any time shall be reduced in proportion to the aggregate amount of funds provided by the INSTITUTE under this Contract in comparison to the aggregate amount of
funds provided by all Participating Funding Sources that contributed to the Project Result and by the INSTITUTE. For the sake of clarity, Participating Funding Sources do not include equity or quasi-equity financing funding sources or debt
arrangements. In calculating such reduced rate, funds from Participating Funding Sources used for Indirect Costs or for any costs of product development, manufacturing, marketing, sales, regulatory approval or similar commercialization activities
shall not be included. In addition, for clarity, the rate shall not be reduced as a result of any funds received from funding sources where such funding sources are not legally or contractually entitled to receive a share of the Revenue with respect
to such Project Result(s). 
 Section D4.03 Statements and Timing of Payments. All payments owed pursuant to this Part 4 shall be made to the Cancer
Prevention and Research Institute of Texas, and are payable on or before the thirtieth day following the end of the calendar quarter in which RECIPIENT receives the Revenue or, in the case of Section D4.04, receives the monetary recovery. For each
payment specified in Section D4.01, the payment shall be accompanied by a statement specifying: (i) the Grant to which the payment relates, (ii) the identities of and amounts funded by all Participating Funding Sources, (iii) the
License 

  
 ***Confidential
Treatment Requested 
 Page D4 

 

 
  

 Agreements to which the payment relates, (iv) the quantity of all Sales of each Commercial Product and
Commercial Service since the last payment, if Sales are applicable to the current payment, (v) the gross consideration from all such License Agreements and Sales, if Sales are applicable to the current payment, and (vi) the amount of the
payment to the Cancer Prevention and Research Institute of Texas. 
 Section D4.04 Recoveries in Enforcement Actions. In the event that RECIPIENT
receives any monetary recovery from its enforcement of Institute-Funded IPR against infringement by a third party, then it shall pay to the State of Texas a share of such monetary recovery, including any punitive damages, less the documented fees
and expenses that are directly associated with such enforcement and are paid by RECIPIENT to third parties, at the same rate and in the same manner as it shares Revenue pursuant to Section D4.01 (including any adjustments allowed by Section D4.02).
For clarity, if the enforcement action is resolved by way of the execution of a License Agreement with the infringing third party, such License Agreement is consistent with the Section D4.01, then this Section D4.04 is not intended to apply to such
License Agreement or the consideration specified therein. 
 Section D4.05 Revenue-Related Records. In addition to satisfying the requirements of
Article IV of the Contract and Section E1.03 of Attachment E, the RECIPIENT shall keep complete and accurate Revenue-related Records until the fourth anniversary of the date of the payment of the last royalty payment owed hereunder, in sufficient
detail to permit the INSTITUTE to confirm the accuracy of the statements delivered to the INSTITUTE under Section D4.03 and the calculation of the royalties owed hereunder. 

Section D4.06 Audit of Revenue-Related Records. Upon at least [...***...] advance written notice, the RECIPIENT shall permit the INSTITUTE or its
representatives or agents, at the INSTITUTE’s expense, to examine the Revenue-related Records of the RECIPIENT pursuant to Section D4.05 at least once per calendar year during regular business hours for the purpose of and to the extent
necessary to verify the RECIPIENT’s compliance with this Part 4. The rights of the INSTITUTE under this Section D4.06 shall terminate on the fourth anniversary of the date of the payment of the last royalty payment owed hereunder. In the event
that any such examination reveals an underpayment to the INSTITUTE of greater than [...***...] percent ([...***...]%) of the amounts previously paid by the RECIPIENT to the INSTITUTE, then the RECIPIENT shall reimburse the INSTITUTE for the cost of
such examination. 
 PART 5 

OPT-OUT AND DEFAULT 
 Section
D5.01 RECIPIENT Opt-Out. Upon receipt of RECIPIENT’s notice of its election (i) under Section D1.03 to abandon any Institute-Funded IPR or (ii) under Section 3.06 to cease its efforts to commercialize or otherwise bring to
practical application any particular Project Results, the INSTITUTE shall have the option, but not the obligation, to pursue protection of the applicable Institute-Funded IPR, including directing the filing, prosecution and maintenance of patents
covering the applicable Institute-Funded Inventions and/or to commercialize or otherwise bring to practical application the applicable Project Results, at its own cost, either directly or through one or more licensees. If the INSTITUTE elects to
exercise such option, it shall notify RECIPIENT in writing within thirty (30) days of its receipt of RECIPIENT’s notice and RECIPIENT shall thereafter comply with the terms of Section D5.03. 

Section D5.02 RECIPIENT Default. In the event that the INSTITUTE notifies RECIPIENT in writing of RECIPIENT’s failure to materially comply with
its obligations under Sections D1.03 or D3.02 with respect to any particular Project Results, and RECIPIENT fails to cure such failure within thirty (30) days of such notice, then the INSTITUTE shall have the option, but not the obligation, to
direct the filing, prosecution and maintenance of patents covering the applicable Institute-Funded Inventions and/or to commercialize or otherwise bring to practical application the applicable Project Results, at its own cost, either directly or
through one or more licensees. If the INSTITUTE elects to exercise such option, it shall notify the RECIPIENT in writing of such election and RECIPIENT shall thereafter comply with the terms of Section D5.03. 

  
 ***Confidential
Treatment Requested 
 Page D5 

 

 
  

 Section D5.03 RECIPIENT Cooperation upon Opt-Out or Default. In the event that the INSTITUTE exercises
its option under Section D5.01 or D5.02, the RECIPIENT shall: 
  

	 	(1)	transfer all of its right, title and interest in and to the applicable Project Results to the INSTITUTE or the INSTITUTE’s designee, to the maximum extent allowed by law, including where relevant and necessary to
facilitate the foregoing transfer, requesting and diligently attempting to obtain any approvals required by law or otherwise in relation to such transfer; 

  

	 	(2)	to the extent that RECIPIENT is unable to transfer all of its right, title and interest in and to the applicable Project Results to the INSTITUTE as specified in item (1), and subject to any existing third party rights,
RECIPIENT hereby grants to the INSTITUTE an exclusive, royalty-free, perpetual, fully transferable license under the applicable Institute-Funded IPR to Exploit the Project Results for the development, manufacture and sale of Commercial Products and
Commercial Services and for all other purposes reasonably related thereto, provided that the INSTITUTE may exercise the foregoing license rights only after exercising its option under Section D5.01 or D5.02; 

 

	 	(3)	fully cooperate with the INSTITUTE’s efforts, and at the INSTITUTE’s cost, in protecting applicable Institute-Funded Inventions and in commercializing or otherwise bringing to practical application the
applicable Project Results, including making relevant Recipient Personnel (to the extent still then-employed by RECIPIENT), Contractors, Collaborators, records, papers, information, samples, specimens and other materials related to the applicable
Institute-Funded Technology reasonably available for such purposes and executing any documents and taking any further action necessary to fully effectuate the intent of this Section; and 

 

	 	(4)	not take any action that would materially impede the INSTITUTE’s ability to protect the applicable Institute-Funded Inventions. 

If the INSTITUTE exercises its option under Sections D5.01 or D5.02, RECIPIENT shall have no further claim or interest in or to the applicable Project Results
(except as set forth in Part 2 of this Attachment, if applicable) and shall not be entitled to any share of Revenue or any other compensation with respect to such Project Results, except to the minimum extent required by law, if any. To the extent
that the INSTITUTE has exercised its option under Section D5.01 or D5.02 and RECIPIENT is unable to transfer all of its right, title and interest in and to the applicable Project Results to the INSTITUTE as specified in item (1), then the
INSTITUTE’s license set forth in item (2) includes the right, but not the obligation, for the INSTITUTE at its cost to: (i) direct the filing, prosecution and maintenance of patents covering the applicable Project Results, and
(ii) enforce all applicable Institute-Funded IPR relevant to the Project Results against any infringement by a third party. Subject to the statutory duties of the Texas Attorney General, if any, RECIPIENT shall cooperate fully with the
INSTITUTE in any action brought by the INSTITUTE to enforce the Intellectual Property Rights in the applicable Project Results, at the INSTITUTE’s cost, including without limitation, joining the enforcement action in name as a party plaintiff
after all required approvals are obtained; provided that the INSTITUTE or its designee shall have full control over such enforcement action and shall receive and retain all monetary recoveries resulting from such enforcement actions, including any
punitive damages. 

  
 Page D6 

 

 
  

 PART 6 

DEFINITIONS 
 The following terms
shall have the following meaning throughout this Attachment. Other terms may be defined elsewhere in this Attachment. 
 (1) Authorized Seller
– RECIPIENT, its Collaborators, or their licensees or any other party authorized by RECIPIENT, its Collaborators or their licensees to make a Sale on their behalf. 

(2) Buyout Trigger Event – the acquisition, by an independent third party (“the Party”), of substantially all of the assets of
RECIPIENT and the Party notifies the RECIPIENT it desires to buy out the Royalty defined by this Contract. 
 (3) Commercial Product –
anything that incorporates, is based on, utilizes or is developed from Project Results and is created by human or mechanical effort or by a natural process and that is capable of being sold, licensed, transferred or conveyed to another party or is
capable of otherwise being Exploited or disposed of, whether in exchange for consideration or not, including without limitation any drug, chemical or biological compound, gene, nucleic acid or nucleic acid sequence, gene therapy, plant, machine,
mechanical device, hardware, tool or computer program. 
 (4) Commercial Service – any service performed that incorporates, is based on,
utilizes or is developed from Project Results. For clarity, Commercial Service does not include research and development performed by RECIPIENT or its Collaborators. 

(5) Exclusive License – a License Agreement under which the specific rights granted to the licensee with respect to the Project Results,
including without limitation scope of use and territorial rights, are granted on an exclusive basis. 
 (6) Exploit – make, have made,
use, sell, offer to sell, import, export or otherwise dispose of, practice, copy, distribute, create derivative works of, publicly perform or publicly display. 

(7) Institute-Funded IPR – any and all Intellectual Property Rights in and to Institute-Funded Technology. In no event shall
Institute-Funded IPR include any intellectual property rights and/or technology in existence and owned/controlled by the RECIPIENT prior to the receipt of funds from the INSTITUTE, the listing of such IPR and/or technology in existence and
owned/controlled by the RECIPIENT prior to the receipt of funds from the INSTITUTE is attached herein. 
 (8) Institute-Funded Invention –
an Invention conceived or first reduced to practice by RECIPIENT, Recipient Personnel and/or Collaborator(s) in the performance of Institute-Funded Activity. 

(9) Institute-Funded Technology – any and all of the following resulting or arising from Institute-Funded Activity during the Contract term:
(a) proprietary and confidential information, including but not limited to data, trade secrets and know-how; (b) databases, compilations and collections of data; (c) tools, methods and processes; and (d) works of authorship,
excluding all scholarly works, but including, without limitation, computer programs, source code and executable code, whether embodied in software, firmware or otherwise, documentation, files, records, data and mask works; and all instantiations of
the foregoing in any form and embodied in any form, including but not limited to therapeutics, drugs, drug delivery systems, drug formulations, devices, diagnostics, biomarkers, reagents and research tools. Institute-Funded Technology includes
Institute-Funded Inventions. In no event shall Institute-Funded Technology include items that were conceived of, in existence, or owned/controlled by RECIPIENT prior to receipt of funds from the INSTITUTE (a) proprietary and confidential
information, including but not limited to data, trade secrets and know-how; (b) databases, compilations and collections of data; (c) tools, methods and processes; and (d) works of authorship, excluding all scholarly works, but
including, without limitation, computer programs, source code and executable code, whether embodied in software, firmware or otherwise, documentation, files, records, data and mask works; and all instantiations of the foregoing in any form and
embodied in any form, including but not limited to therapeutics, drugs, drug delivery systems, drug formulations, devices, diagnostics, biomarkers, reagents and research tools,. 

  
 Page D7 

 

 
  

 (10) Intellectual Property Rights – any and all of the following and all rights in,
arising out of, or associated therewith: (a) all United States and foreign patents and utility models and applications therefor, and all reissues, divisions, renewals, extensions, provisionals, and continuations and continuations-in part
thereof, and equivalent or similar rights anywhere in the world in inventions and discoveries; (b) all trade secrets and rights in know-how and proprietary information; (c) all copyrights, copyright registrations and applications therefor,
and all other rights corresponding thereto throughout the world; (d) all mask works, mask work registrations and applications therefor, and any equivalent or similar rights in semiconductor masks, layouts, architectures or topology; and
(e) any similar, corresponding or equivalent rights to any of the foregoing anywhere in the world. 
 (11) Invention – a method,
device, process or discovery that is conceived and/or reduced to practice, whether patentable or not. 
 (12) License Agreement – an
agreement by which an owner of a Project Result grants any right to Exploit such Project Result to another party in exchange for consideration. 
 (13)
Licensing Activities – the efforts of RECIPIENT or its Collaborator to negotiate, execute or enforce a License Agreement. 
 (14)
Necessary Additional IPR – any unencumbered Intellectual Property Rights (a) owned by RECIPIENT, and (b) identified by the Institute and agreed to in writing by Recipient, that are not Project Results but are necessary
to Exploit the Project Results for the specific purposes set forth in the applicable Section of this Attachment D. 
 (15) Non-Exclusive
License – a License Agreement under which the rights granted to the licensee with respect to the Project Results are granted on a non-exclusive basis. 
  

	(16)	Project Results – any and all Institute-Funded Technology and Institute-Funded IPR. 

 (17)
Revenue – the gross consideration, whether cash or non-cash (e.g., securities, direct equity interest, indirect equity interest, etc.), received from Sales and License Agreements related to Project Results (including without
limitation, any milestone fees, license fees, sublicense fees, assignment fees, product royalties and similar fees and royalties), net of (a) trade or quantity discounts or rebates, credits, allowances or refunds given for rejected or returned
Commercial Products or Commercial Services, (b) any sales, value-added or other tax or governmental charge levied on the sale, transportation or delivery of a Commercial Product or Commercial Service (but excluding any income tax owed by the
RECIPIENT), and (c) any separately stated charges for freight, postage, shipping and insurance. 
 (18) Sale – means any sale, lease,
transfer, conveyance or other exploitation or disposition of a Commercial Product or Commercial Service for which consideration is received by an Authorized Seller. 

  
 Page D8 

 

 
  

 ATTACHMENT E 

REPORTING REQUIREMENTS 
 This Attachment E
is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (“Contract”) by and between the Cancer Prevention and Research Institute of Texas (“CPRIT” or the
“INSTITUTE”) and the RECIPIENT. A capitalized term used in this Attachment shall have the meaning given to term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a
conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. 
 INSTITUTE and RECIPIENT agree as
follows: 
 ANNUAL REPORTING 

Section E1.01 Annual Reports. The RECIPIENT shall submit reports annually to the INSTITUTE within 60 days of the anniversary of the Effective Date of
this Contract or at such other time as may be specified herein. The reports shall be submitted by the means and in the form(s) required by the INSTITUTE and shall be signed by the Principal Investigator/Program Director and the RECIPIENT’s
Authorized Signing Official. To the extent possible, the reports shall only include information that may be shared publicly. However, if it is necessary to submit information in the reports that the RECIPIENT considers confidential in order to fully
comply with the terms of this Contract, then the RECIPIENT shall use reasonable efforts to mark such information as “confidential” and shall, to the extent practicable, to segregate such information within the reports to facilitate its
redaction should redaction ever be necessary or appropriate. 
 Section E1.02 Contents of Reports. Each report shall contain a signed verification
(electronic signature is acceptable) of RECIPIENT’s compliance with each of its obligations as set forth in the Contract and shall include the following for the period covered by such report, as may then be applicable: 

(a) Project Data. During the term of the Contract, RECIPIENT shall include in its annual report each of the following (except that the final annual
report due under this part (a) shall be due within ninety (90) days after the end of the term of the Contract): 
  

	 	(1)	A brief statement of the progress made to under the Scope of Work, including the progress to achieve the Project Goals and Timelines set forth in Attachment A. 

 

	 	(2)	A brief statement of the Project Goals for the twelve months following submission of the report. 

  

	 	(3)	New jobs created in the preceding twelve month period as a result of the Grant funds awarded to RECIPIENT. 

  

	 	(4)	An inventory of the Equipment purchased for the Project using Grant funds. 

  

	 	(5)	A HUB report in accordance with Section 3.08 “Historically Underutilized Businesses” of the Contract. 

(b) Commercialization Data. During the term of the Contract and continuing thereafter for so long as RECIPIENT has ongoing obligations to the INSTITUTE
with respect to protection, development, commercialization and licensing of Project Results pursuant to Attachment D, RECIPIENT shall provide information about commercialization activities in a format specified by the INSTITUTE. 

  
 Page E1 

 c) Revenue Sharing Data. During the term of the Contract and continuing thereafter for so long as
RECIPIENT has ongoing obligations to the INSTITUTE with respect to revenue sharing pursuant to Attachment D: 
  

	 	(1)	A statement of the identities of the funding sources, amounts and dates of funding for all funding sources for the Project. 

  

	 	(3)	A brief statement of the RECIPIENT’s efforts to secure additional funds to support the Project. 

  

	 	(4)	All financial information necessary to verify the calculation of the revenue sharing amounts specified in Attachment D. 

(d) Additional Data. In addition to the foregoing, RECIPIENT shall use commercially reasonable efforts to also promptly report any other information
required by this Contract or otherwise reasonably requested by the INSTITUTE, the Legislature, or any other funding or regulatory bodies covering the RECIPIENT’s activities under this Contract. 

Section E1.03 Record Keeping and Audits. The provisions of Article IV of the Contract shall apply fully to all information reported to the INSTITUTE
pursuant to this Attachment, except that the right of the State of Texas to audit and the RECIPIENT’s obligation to maintain Records shall continue until four years after the date of each such report made by RECIPIENT hereunder. 

Section E1.04 Confidentiality of Documents and Information. The provisions of Section 2.13 “Confidentiality of Documents and
Information” of the Contract shall apply fully to all Confidential Information reported, delivered or submitted to the INSTITUTE pursuant to this Attachment E. 

  
 Page E2 

			
	

	  	 ATTACHMENT F-1
  

RP110508

 By their signatures below, parties hereby agree that the effective date of this contract as reflected in Section 2.03 is
changed to July 1, 2011and the end date is June 30, 2013. 
  
 Further, in
accordance with Section 2.03, this amendment serves as specific authorization for RECIPIENT to expend grant funds prior to the effective date of the contract, so long as the expenses are not incurred prior to June 1, 2011. 

EXECUTED IN DUPLICATE ORIGINALS ON THE DATES INDICATED. 
  

									
	RECIPIENT	 		 	INSTITUTE
				
	By	 	 /s/ Thomas J. Farrell
	 		 	 /s/ William Gimson

	(Signature of Person Authorized to Sign Contracts)	 		 	(Signature of Person Authorized to Sign Contracts)
	Name: Thomas J. Farrell, CEO	 		 	  Name: William “Bill” Gimson, Executive Director
	Date: August 25, 2011	 		 	  Date: June 22, 2011

  

			
	

	  	ATTACHMENT F-2

 As indicated by the signatures below, the INSTITUTE and the RECIPIENT agree to the following amendments to the CPRIT Contract:

 Section 4.03 Inspections. 
 The first
sentence of Section 4.03 is hereby amended to read in its entirety as follows: 
 “In addition to the audit rights specified in Section 4.02
‘Audits’, during the term of this Contract, the INSTITUTE shall have the right to conduct periodic onsite inspections within normal working hours and on a day and a time mutually agreed to by the parties, to evaluate the Institute-Funded
Activity.” 
 Section 4.07 Repayment of Grant Proceeds for Relocation Outside of Texas. 

Section 4.07 is amended by adding the following sentence to the end of the Section: 

“The RECIPIENT shall repay the INSTITUTE all Grant proceeds disbursed to RECIPIENT and a preferred return of [...***...]% of the amount disbursed in the
event that RECIPIENT relocates its principal place of business outside of the State during the Contract term or within 3 years after the final payment of the Grant funds is made by the INSTITUTE. Upon repayment to the INSTITUTE of all Grant funds
disbursed to RECIPIENT and the preferred return of [...***...]% of the amount disbursed, the Contract shall terminate and RECIPIENT shall have no further obligations to the INSTITUTE hereunder.” 

AMENDMENTS TO ATTACHMENT D 
 Section D2.02 INSTITUTE
License. 
 Section D2.02 of Attachment D is here by amended by adding the following sentence to the end of the section: 

“All other rights are reserved by RECIPIENT.” 

Section D3.01 Commercialization Strategy. 
 Section
D3.01 of Attachment D is hereby amended by deleting the period in the last sentence and inserting the following language after the word “strategy”: 

“, that RECIPIENT, in its sole business judgment, decides to incorporate.” 

EXECUTED IN DUPLICATE ORIGINALS ON THE DATES INDICATED. 
  

					
	RECIPIENT	  	INSTITUTE

					
			
	By	 	 /s/ Thomas J. Farrell
	  	 /s/ William Gimson

	(Signature of Person Authorized to Sign Contracts)	  	(Signature of Person Authorized to Sign Contracts)
	Name: Thomas J. Farrell, CEO	  	Name: William “Bill” Gimson, Executive Director
	Date: August 31, 2011	  	Date: August 31, 2011

  

  
 ***Confidential
Treatment Requested 

			
	

	  	 ATTACHMENT F-3
  

RP110508

 As indicated by the signatures below, the INSTITUTE and the RECIPIENT agree to the following amendments to the CPRIT Contract:

 AMENDMENT TO SECTION 2.03 
 The end date
indicated in Section 2.03 of the CPRIT Contract is hereby changed to June 30, 2014. 
 EXECUTED IN DUPLICATE ORIGINALS ON THE DATES INDICATED.

  

			
	RECIPIENT	  	INSTITUTE
		
	 By /s/ Thomas J. Farrell

(Signature of Person Authorized to Sign Contracts)
	  	 /s/ William Gimson

(Signature of Person Authorized to Sign Contracts)

	Name: /s/ Thomas J. Farrell	  	Name: William “Bill” Gimson, Executive Director
	Date: October 28, 2011	  	Date: October 24, 2011

 CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS 

REQUEST FOR ADVANCEMENT OF GRANT AWARD 
  

							
	 ENTITY:
	  	Bellicum Pharmaceuticals, Inc.
	
ADDRESS:
	  	6400 Fannin St, Suite 2300, Houston, TX 77030
	
PI:
	  	Kevin M. Slawin, M.D.
	 	 
	 CPRIT GRANT NUMBER:
	  	RP110508
	 	  	 	  	 	  	 
	BUDGET CATEGORIES	  	 CURRENT YEAR APPROVED

BUDGET
	  	ADVANCE AMOUNT
REQUESTED	  	Percentage of
Funds
Advanced
	 	 	 	 
	
PERSONNEL
	  	[...***...]	  	[...***...]	  	 
	 	 	 	 
	 FRINGE
BENEFITS
	  	[...***...]	  	[...***...]	  	 
	 	 	 	 
	
TRAVEL
	  	[...***...]	  	[...***...]	  	 
	 	 	 	 
	
EQUIPMENT
	  	[...***...]	  	[...***...]	  	 
	 	 	 	 
	
SUPPLIES
	  	[...***...]	  	[...***...]	  	 
	 	 	 	 
	
CONTRACTUAL
	  	[...***...]	  	[...***...]	  	 
	 	 	 	 
	 OTHER
	  	[...***...]	  	[...***...]	  	 
	 	 	 	 
	 TOTAL
	  	[...***...]	  	[...***...]	  	100.00%
	 	  	 	  	 	  	 
	
Justification for Advancement of Grant Award Funds

funds required to achieve first major project milestone

 

	 	  	 	  	 	  	 
	 
	 Acknowledgement, I
understand that the advancement of grant funds does not preclude the fiscal requirements (timely submission of financial reports, allowable expenditures, indirect cost less then five percent, etc.) of the grant award.

 

	 	  	 	  	 	  	 
	
Signature of Authorized Certifying Official:
  

/s/ Thomas J. Farrell
  
	  	 Telephone Number

713-341-6472
	  	 Date

8/29/2011

	 
	
Typed or Printed Name and Title of Certifying Official:

Thomas J. Farrell, CEO

 

 ***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]